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1.0 Abstract 
Background  
There is significant variation in clinical outcome between patients diagnosed with 
prostate cancer (CaP). Although useful, statistical nomograms and risk stratification 
tools alone do not always accurately predict an individual’s need for and response to 
treatment. As a result there remains a need to identify and validate biomarkers for 
predicting prostate cancer outcomes using robust and routinely available pathology 
techniques to recognize men at most risk of premature death due to prostate cancer. 
 
The day-to-day treatment options available to clinicians are continually evolving, with 
newer technologies and a greater understanding of the tumour biology prompting 
innovative approaches. However, despite this, all techniques have considerable 
associated side effects and there is a great deal of disagreement regarding which 
patients need radical treatment and which can be safely monitored, therefore avoiding 
unnecessary morbidity. 
 
If more accurate risk stratification can be achieved using newly developed biomarkers 
(probably in addition to conventional staging techniques) then the aim is to reduce 
unnecessary treatment and assist timely and appropriate surgical and oncological 
intervention.  
 
Aims and Objectives 
We aimed to develop biomarkers predictive of outcome in prostate cancer, in 
particular ones that could be used in a mainstream NHS laboratory to help clinicians 
and patients make informed decisions regarding the management of their disease. We 
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also intended to investigate whether bioinfomatic techniques such as artificial neural 
network analysis (ANN) could play a role in prostate cancer biomarker identification. 
We also felt it was important to validate our clinical data set and associated tissue 
micro array (TMA) by comparing its performance against previously identified 
biomarkers shown to have predictive utility in prostate cancer.  
  
Methods  
A tissue microarray (TMA) was constructed from transurethral resection of prostate 
(TURP) and transrectal ultrasound-guided (TRUS) prostate biopsy samples that were 
histologically proven to demonstrate prostate cancer. Patients had undergone these 
procedures either to deal with troublesome urinary symptoms or had presented with 
an elevated prostate specific antigen (PSA) blood test. A comprehensive clinical data 
set of parameters conventionally used to decide upon treatment and monitor clinical 
response was collected. ANN analysis was used to identify candidate markers 
conferring increased risk of death and metastasis interrogating a public cDNA array, 
alongside a conventional literature review identifying previously published 
biomarkers that could be used to validate the TMA and clinical dataset. 
Immunohistochemical analysis of the TMA was carried out and univariate and 
multivariate tests performed to explore the association of tumour protein levels of 
identified biomarkers with various clinical endpoints, particularly time to death and 
metastasis.  
 
Results  
We successfully demonstrated associations between various biomarkers, and in 
particular validated our TMA and clinical dataset against the previously published 
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marker Ki67, showing that Ki67 is predictive of CaP-specific survival and 
development of future metastases. In addition we were able to identify an entirely 
novel prostate cancer marker, DLX2, using artificial neural network analysis and 
demonstrate it has a statistically significant association with the development of 
prostate cancer metastases. 
 
Conclusion 
The Nottingham TMA has been shown to have utility in the investigation of candidate 
biomarkers in prostate cancer. We have also demonstrated that bioinfomatic 
techniques such as artificial neural network analysis can be employed to isolate 
candidate markers. During this work we have identified two cancer cell proliferation 
markers, Ki67 and DLX2, that may be able to inform clinical decision making when 
identifying patients for suitable for prompt active treatment versus active surveillance. 
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2.0 Introduction 
Prostate cancer (CaP) is the most common male malignancy in the United Kingdom 
with an incidence of 176.4 per 100,000 in 20151. It is the second most common male 
cancer worldwide2  and confers significant morbidity and mortality. With rising 
incidence it is a tremendous health economic burden, with annual expenditure in the 
UK of £94.2 million and in the US of $11.5 billion in 2010 alone3. 
 
Diagnosis of CaP is based on clinical examination of the prostate, serum prostate 
specific antigen (PSA) levels and histological assessment. Assessment of tumour 
aggression is based on the Gleason grading system. This was developed by Dr Donald 
Gleason, a pathologist in the USA, in the 1970s and has remained the single most 
important diagnostic and prognostic component in CaP assessment and treatment. The 
Gleason score is based on a microscopic examination of prostate tissue. The most 
common architectural pattern is identified and graded on a scale of 1 to 5 (5 being the 
most aggressive) and then the second most common architectural pattern is similarly 
graded. The two scores are then added together giving a total out of 10. More 
information on the Gleason score can be found in section 2.3. 
 
While technology has evolved quickly, particularly in the field of imaging used to 
identify and stage prostate cancer, the formal diagnosis still rests on histological 
analysis of prostate tissue samples. Since the 1980s the most common technique of 
acquiring tissue for targeted diagnosis has been using a trans-rectal needle biopsy. 
Initially the method involved taking 6 cores, 3 from each lateral lobe, but over the 
years evolving to employing a ‘sextant’ pattern of 12 cores, 6 from each lateral lobe. 
The procedure is usually guided by an ultrasound probe inserted into the rectum, and 
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covered with injected local anaesthetic. Despite this the procedure is still extremely 
uncomfortable for the patient, particularly in the early stages of inserting the 
ultrasound probe, as the local anaesthetic can only be inserted once this is done. The 
procedure also confers a risk of rectal bleeding and infection, which in approximately 
1% of patients can necessitate admission to hospital with sepsis and the need for 
intravenous antibiotics. The benefits of the procedure are that it is relatively cheap, 
easy to learn and can be performed in an outpatient setting.  
 
More recently attention has turned to trans-perineal prostate biopsies, which involve 
multiple needle biopsies taken through the perineum, again guided by a rectal 
ultrasound probe, but carried out under general or spinal anaesthesia. Trans-perineal 
biopsies have been repeatedly demonstrated to find higher-grade cancer in 
approximately 40% of patients originally diagnosis with TRUS biopsies4. This is 
thought to be due to the techniques ability to access the anterior aspect of the prostate 
and also through a simple increase in the volume of tissue taken (approximately 40-50 
cores compared to a ‘standard’ 12 in TRUS biopsy). The trans-perineal approach has 
far less risk of infection, but does have a higher (approx. 10%) risk of triggering a 
period of urinary retention. It is also much more expensive and labour intensive, 
requiring a full theatre team, general anaesthetic and often an overnight stay in 
hospital.  
 
In a resource limited NHS, many Trusts have taken the pragmatic approach to 
perform TRUS biopsy in the initial setting and if the patient is thought suitable for 
surveillance rather than radical treatment (for example if the TRUS biopsy shows 
Gleason 6 or low volume Gleason 3+4) then proceeding to trans-perineal biopsies to 
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ensure that the patient is not one of the 40% who are upgraded and therefore may 
indeed have to undergo radical treatment.  
 
There are various ways to stage prostate cancer, and a combination of modalities are 
usually employed. Clinical staging is based on a digital rectal examination of the 
prostate and if an abnormality is felt can be described as: 
 
Stage 2a A tumour involving less than half of one lobe of the prostate 
Stage 2b A tumour involving more than one half of one lobe of the prostate 
Stage 2c Tumour involving any amount of both lobes of the prostate 
Stage 3 Tumour likely to have grown beyond prostatic capsule 
Stage 4 Tumour has involved other surrounding organs 
 
By definition impalpable disease cannot be staged clinically, so stage 1 disease is 
based on histological analysis of tissue. 
 
In addition, the staging can be further subdivided when histological and imaging 
information becomes available. 
 
Prostate cancer is also diagnosed from tissue not taken with the primary goal of 
looking for cancer. A commonly performed procedure, transurethral resection of 
prostate (TURP) is carried out to improve the urinary flow from the bladder that was 
being prevented from emptying efficiently by prostatic overgrowth. Here, the 
prostatic tissue surrounding the urethra is ‘resected’ (usually cut with a heated loop of 
wire), leaving a larger channel for urine to flow through and the resected tissue is 
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routinely sent to the laboratory for analysis. Given that this operation is performed 
most frequently in older men, and prostate cancer is more common as men get older, 
it is not unlikely that a diagnosis of prostate cancer will be made. If this occurs they 
should be staged in the same way as biopsy-proven disease. 
 
Correlation between the above staging factors and subsequent cancer outcomes has 
led to the development of well validated risk stratification tools5 that broadly classify 
newly diagnosed patients into low (47%), intermediate (38%) and high (15%) risk 
groups6,7. These tools, and meticulously populated nomograms8,9, continue to inform 
clinical decision making during the investigation, management and follow-up of 
prostate cancer10.  
 
However, it is increasingly apparent that these tools alone are not sufficient to 
determine an individual’s likelihood of being affected by clinically significant disease, 
particularly in the large ‘intermediate’ risk group, which accounts for approximately 
38% of patients. Some patients require radical treatment but in others their disease is 
likely to remain indolent, having no demonstrable effect on their quality of life, or 
indeed life expectancy. 
 
Over the last decade there has been increasing recognition that most patients with low 
risk disease do not require radical treatment, as they are unlikely to die from their 
disease. Major studies published recently have confirmed this observation, 
demonstrating no survival benefit from radical treatment in any patient group with 
low risk disease11. As a result, both the National Institute for Clinical Excellence 
(NICE) and the European Association of Urology  (EAU) guidelines suggest active 
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surveillance (close monitoring of patients’ PSA and follow-up biopsies) as first line 
management in low risk disease12,13. 
 
The factors that determine this variation in cancer aggression between patients are not 
fully elucidated. In particular, cellular response to androgen ablation and subsequent 
paracrine/autocrine adaptation is poorly understood and despite best therapies, median 
survival in castrate resistant patients is only approximately 35 months14. 
 
Prostate cancer is an extremely heterogeneous disease process and further work is 
required to characterise its complex molecular biological mechanisms and genetic 
aberrations. This heterogeneity presents obstacles and opportunities for identifying 
and developing more accurate diagnostic and prognostic tests and new therapeutic 
avenues. There is now a realisation that CaP has an intricate relationship with its 
stromal microenvironment15,16 and it may develop from different progenitor cells 
resulting in cancers with basal and luminal lineages, resulting in divergent disease 
pathways17. 
 
Increasingly there is awareness that many malignancies share causative, 
pathophysiological and genetic features. Prostate cancer and breast cancer share a 
number of these characteristics. It is now recognised that breast cancer has multiple 
genetic phenotypes reflecting the tumour cell of origin and cell signalling pathways 
involved in disease progression and are generally characterised by differing patient 
outcomes18–20.  However the biggest impact on survivorship has arguably resulted 
from advances in targeted adjuvant therapy derived from the identification of 
individual cell surface protein receptors on primary tumours. In operable breast cancer, 
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surgical excision with adjuvant chemotherapy and radiotherapy is performed to 
remove and ‘sterilise’ residual proliferating cancer cells. In addition adjuvant 
hormonal therapy is given to inhibit growth in oestrogen receptor responsive cancers, 
or the humanised antibody, trastuzumab, to inhibit growth and metastasis in patients 
with cancers expressing HER221.  
 
There are similarities in the treatment approach used for prostate cancer, but the 
repertoire of therapeutic options is more restricted. The mainstay curative treatments 
for localised prostate cancer are surgical prostatectomy alone or radiotherapy 
combined with a period of chemical castration involving hormonal-based androgen 
deprivation therapy (ADT) whose primary purpose is to prevent testosterone-
responsive growth in any residual viable tumour cells22. However, 20-30% of patients 
treated for localised prostate cancer will fail therapy and require long term ADT23.  
Unfortunately, castrate-refractory disease is essentially inevitable at some point along 
the disease pathway, associated with poor prognosis due to metastasis formation. 
Therefore, there remains an unmet need to inhibit metastasis formation, possibly 
resulting from circulating tumour cells24 or the activation of dormant disseminated 
tumour cells (DTCs) present at the time of diagnosis25. Crucially, it has been proposed 
that the biology of DTCs is fundamentally different to the primary tumour supporting 
the need for characterisation of DTCs so that appropriate therapeutic approaches can 
be designed to successfully neutralise the threat posed by DTCs26 . Novel combinative 
strategies that target the primary and disseminated tumour cells may be required to 
achieve significant improvement in treatment success. 
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As described above, treatment for prostate cancer with curative intent is described as 
‘radical’ treatment. In the vast majority of cases this is either approached from a 
surgical perspective or through radiotherapy. The decision of which route to take is 
based on a multi-disciplinary team meeting, involving Urologists, Oncologists, 
Radiologists, Pathologists and associated support specialities. The meeting is an 
obligatory part of the clinical decision making process and will issue a 
recommendation that is subsequently discussed with the patient. The patient can then 
choose to accept the recommendation (sometimes various options are presented to 
them) or with the help of their medical team discuss other options that may not 
necessarily be considered ‘first line therapy’. If the patient has capacity and 
understands the risks of not following the initial recommendation then every effort is 
made to assist them with their choice of therapy. 
 
Historically, the mainstay of radical prostate surgery has been the open prostatectomy. 
Most frequently this involved a lower midline incision, dissection of the prostate from 
the bladder and the bulbar urethra and then re-anastamosis of the bladder to the 
urethral stump. This procedure is still occasionally carried out in the UK, but has 
largely been superseded by laparoscopic radical prostatectomy (LRP) and more 
recently robot-assisted radical prostatectomy (RARP), both of which aim to achieve 
the same result, but are more ‘minimally-invasive’.  While each evolution of the 
procedure has improved recovery time (for example a patient would likely remain in 
inpatient for 7 days post open surgery, but for only 1 day following RARP) and 
lessened surgical complications there are still risks associated with the approach. Even 
with extremely experienced surgeons patients should expect at least a 50% chance of 
erectile dysfunction (permanent) post-procedure, up to 12 months of varying degrees 
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of urinary incontinence (5% with permanent problems) and a 0.5% risk of serious 
rectal injury necessitating an emergency bowel stoma. In addition there are the normal 
surgical risks including, but not limited to, bleeding, infection, deep vein thrombosis 
and pulmonary embolus. Clearly surgical intervention should not be taken lightly. 
 
Radical radiotherapy can either be delivered by an external beam approach, or via 
insertion of radioactive seeds or temporary radioactive probes known as 
‘brachytherapy’. While an advantage of radiotherapy over surgery is its lack of 
immediate significant complications, it certainly has inevitable consequences. Erectile 
dysfunction is delayed, but has a similar incidence to that of surgery. Incontinence is 
less frequent, but radiotherapy can trigger lower urinary tract symptoms such as 
urinary frequency and urgency and can exacerbate pre-existing symptoms. In addition 
radiotherapy can cause rectal irritation and inflammation leading to diarrhoea and 
rectal bleeding. It can also lead to urethral/bladder neck strictures (although so can 
surgery in certain circumstances). A major issue of radiotherapy is that it can trigger 
secondary malignancies, usually 10 to 20 years after treatment, and confers a relative 
risk of bladder cancer of approximately 1.3. In addition radiotherapy, particularly 
external beam, is highly time consuming and a typical regimen would involve coming 
to hospital every weekday for 6-7 weeks, which in younger patients who are still 
working is an extremely challenging logistical issue. 
 
There is no convincing evidence of surgery or radiotherapy being superior when 
assessed against cancer survival. Most studies have been hard to interpret as 
historically older, less fit patients have been offered radiotherapy rather than surgery 
so would inevitably not do so well when compared with younger, fitter patients 
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undergoing surgery. One commonly used argument, particularly when counselling 
younger patients who would be anticipated to live for many years is that if they 
undergo surgery primarily and the disease returns, then radiotherapy is an option at 
that stage. If a patient has radiotherapy up front and the disease returns then ‘salvage’ 
surgery is extremely difficult as the tissues are very damaged from radiation exposure 
and are therefore very hard to operate on, with a much higher complication rate. Many 
surgical units do not offer salvage surgery, as this is highly sub-specialised. 
 
2.1 Prostate epithelial cell lineage 
Anatomically the prostate has a lobular structure, with lateral and anterior lobes. 
However, seminal work by McNeil described a zonal architecture, with each zone 
demonstrating different characteristics and propensity to develop cancers. The three 
main cellular populations are the luminal columnar epithelial cells that line the 
approximately 30 prostatic ducts, the basal epithelial cells on which the luminal cells 
rest and small numbers of neuroendocrine cells within the basal layer27,28. In addition, 
anteriorly is a mixture of smooth muscle and fibrous tissue, the fibromuscular stroma. 
There is accumulating evidence that malignant potential, disease aggression and 
prognosis may be determined by the subset of cells from which the cancer is derived. 
 
The majority of malignancies are thought to develop in epithelial cells located in the 
peripheral zone, whereas the majority of benign prostatic hyperplasia develops in the 
transitional zone. 
 
There has been considerable debate as to the cell lineage pathways of prostate 
epithelium. It is becoming apparent that the basal compartment contains a pool of 
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multipotent stem cells29–32 that are capable of differentiation into basal and secretory 
luminal epithelium. These different cellular subtypes can be identified through 
discrete expression patterns of certain cell surface proteins. For example luminal cells 
commonly express cytokines (CKs) 8 and 18, whereas basal cells express CK 5 and 
1428. However, further work has demonstrated an ‘intermediate’ cell type that co-
express these markers along with others such as CD2433,35. This intermediate 
population is believed to represent a transition or amplification stage in the 
progression from multipotent stem cells to more differentiated basal and luminal 
epithelium33. 
 
Further work has shown that human basal cells in vivo can be triggered to develop 
prostate cancer when exposed to common gene mutations34. This evidence fits with a 
hypothesis that stem cells are highly likely to be the origin of CaP as they have an 
inherent ability to self-renew, and their subsequent longevity provides sufficient time 
for repeated genetic mutations to finally trigger carcinogenesis. 
 
However, the question at which point in the cellular differentiation pathway CaP is 
initiated remains. Evidence is growing that there are also populations of luminal cells 
that retain some stem-cell like qualities, perhaps because they are still ‘early’ in the 
differentiation phase35, or because they derive from an entirely separate stem cell 
population36,37. The lineage of prostate epithelial cell development has certainly not 
yet been fully mapped, and as a result the exact cell, or cells, of origin of prostate 
cancer remain uncertain. Another unanswered question is whether the cell of origin 
determines tumour aggression, metastatic potential and likelihood of developing 
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castrate resistance as it has recently been proposed that selective clonal stem cell 
expansion is associated with prostate cancer aggressiveness38. 
 
2.2 Circulating tumour cells 
Isolation of circulating prostate cancer cells has been shown to be prognostic in 
prostate cancer24,39. Also, it has been shown that the activation of dormant 
disseminated tumour cells (DTCs) and consequential metastasis involves a balance 
between three opposing processes: cellular dormancy (mitotic arrest); angiogenic 
dormancy (vascular-delivered nutrient restriction); and immune-mediated dormancy 
resulting from immune system cytotoxicity40. Procedures exist for the isolation of 
DTCs41 and biomarkers have been proposed for assessment of their functional state. 
 
Interestingly, given that part of this project has been to study the association between 
stem cell markers and cancer, some of proteins expressed in stem cell populations 
have been implicated in DTC function and control. For example, HER2 is commonly 
expressed in DTCs of various cancers, in particular those displaying a stem-cell like 
phenotype42. Further work has shown that prostate cancer DTCs have the ability to 
replace haematopoietic stem cells of the bone marrow stem cell ‘niche’43 and that this 
environment can promote cellular dormancy of the DTCs, rendering them less 
sensitive to taxotere chemotherapy and thus enable them to ‘weather the storm’ of 
treatment and emerge to seed metastases as some point after chemotherapy has 
finished. These ‘dormancy enriched’ DTCs have recently been found to express lower 
than usual levels of Ki6744, another marker we have examined in this project. Also, 
evidence has emerged that DTCs are likely to differ from their primary tumour at both 
the genomic and gene expression level, leading to differences seen in the marker 
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profile between primary tumour and metastatic tissue and indeed between different 
sites of metastasis45  
 
Circulating tumour cells may offer the possibility of a ‘liquid’ biopsy, which could 
potentially obviate the need for conventional trans-rectal or template tissue biopsies 
and avoid their attendant risks. Currently there are many studies evaluating the utility 
of using CTCs in a diagnostic role, but this technique is certainly not being used in 
clinical practice at present. CTCs are perhaps more likely to be used as part of a 
predictive/prognostic array to help stratify an individual patient’s risk of progression 
of prostate cancer, such as developing metastases. 
 
2.3 Molecular classification of breast cancer and the parallels to prostate cancer 
Prostate cancer and breast cancer share a number of characteristics. For this reason it 
can be postulated that they might share similar approaches for investigating disease 
pathways and identifying biomarkers for clinical management. Both prostate and 
breast cancers are hormonally manipulated, the stromal microenvironment plays an 
integral role in each and they are more common in the presence of certain gene 
mutations such as BRCA1 and BRCA246,47. Clearly, it is important to review the 
evidence for the possible existence of different molecular phenotypes in prostate 
cancer to assess if classification could lead to similar risk profiling and specific 
targeted therapies utilised in breast cancer. 
 
It is now recognised that breast cancer has multiple genetic phenotypes that were 
initially identified by gene expression profiling (GEP)48. This technique was used to 
identify differentially expressed intrinsic genes in breast cancer and subsequent 
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hierarchical clustering models to define four molecular classes: normal breast, luminal 
(oestrogen receptor (ER) positive), basal-like and HER2 (epithelial growth factor 
receptor 2; ERBB2 gene/neu). Subsequent work demonstrated further subtypes such 
as luminal A and B and claudin-low49.  
 
An important aspect of this work was the association between molecular subtype and 
cancer specific survival, allowing the development of risk assessment and targeted 
therapy based on gene/protein expression profiling. These were the first steps towards 
personalised cancer treatment, which is now accepted as the gold standard in 
oncology. 
 
2.3.1 Luminal-like prostate cancer 
Similar to breast cancer, over the last decade many studies concluded that CaP derives 
mainly from terminally differentiated luminal cells, based on the observation that the 
majority of cancer specimens stained negative for basal cell markers and the cell 
surface protein p6350,51. However, other studies suggest that CaP is by no means a 
homogenous entity. Although the absence of P63 is used as an adjunct in the 
histological classification of CaP52, it is occasionally expressed in prostate cancer 
tissue, with higher rates of expression in tissue with higher Gleason scores51. 
 
Androgen receptor (AR) signalling is critical in the development of normal prostate 
tissue and is analogous to the ER in breast tissue. Like the ER in breast cancer, the 
androgen receptor also plays a key role in mediating the various stages of prostate 
cancer and subsequent castrate resistance. AR ‘promiscuity’ is likely to contribute to 
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this process by triggering transcriptional activation in response to antiandrogens or 
other endogenous hormones53.  
 
Development of castrate resistance in advanced prostate cancer is associated with 
poor clinical outcome. Identifying which patients will succumb is currently a key 
research objective to aid clinical management and identify novel targets for therapy. 
The AR receptor and related genes are also implicated in the durability of ADT 
treatment.  Fujimura et al proposed two panels of gene expression markers for 
determining clinical failure (defined by PSA recurrence) and cancer specific survival 
in treatment naïve prostate cancer patients with bone metastasis54. They found 
expression of Sox2, Her2 and CRP in cancer cells to be predictive of clinical failure; 
panels comprising Oct1, TRIM36, Sox2 and c-Myc AR, Klf4 and ERα were found to 
be prognostic of survival in cancer and stromal cells respectively. 
 
2.3.2 Basal-like prostate cancer 
In breast cancer, the basal phenotype has been shown to be associated with more 
aggressive disease, poor patient outcomes and as yet has no specific targeted 
treatment55,56. The basal phenotype is commonly defined by a lack of expression of 
oestrogen receptor, progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) and has been referred to in many papers as the ‘triple negative’ 
phenotype. However evidence now suggests that the basal and triple negative types 
may actually be two distinct groups, albeit with similar poor clinical outcomes57,58, 
although the two terms are still used interchangeably in many recent studies. In 
prostate cancer, the steroid nuclear androgen receptor is expressed in luminal, basal 
and stromal cells, but importantly its regulatory function varies with each population. 
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It enhances cell survival in luminal cells, stimulates proliferation and metastases in 
stromal cells and suppresses proliferation and metastasis in basal cells respectively59. 
 
There is strong evidence demonstrating the basal phenotype as a cell of origin for 
some prostate cancers. Recent work has suggested that genetic signatures commonly 
associated with embryonic stem cells (ESCs) are up regulated in the tumours of 
patients with more poorly differentiated prostate cancers60,61. Interestingly, the same 
characteristic ESC signature has been found in high grade breast cancers, particularly 
the basal subtype62. ESC+ prostate cancers have been associated with higher Gleason 
scores and poorer prognosis than those not expressing this signature. The population 
of phenotypically positive prostate stem cells (PPSC) was higher in metastatic bone 
cancer compared to the primary prostate cancer63. Columbel et al suggest using the 
putative stem cell markers integrin alpha-2 or -6 in combination with c-met and a 5% 
cutoff threshold to predict reduced survival associated with bone metastasis. 
Interestingly, these markers appear to be confined to stem cells localised in the basal 
cell layer of normal and benign prostate hyperplasia tissue64. 
 
Contradicting the existence of a pure basal class of prostate cancer is the observation 
that basal prostate cancer cells tend to lose their basal-defining cell marker 
characteristics and transform into a more luminal phenotype. However, although 
appearing histologically homogenous, prostate cancers still maintain lineage-specific 
genetic signatures.  In contrast to breast cancer, basal cell derived cancers appear to be 
a rarer event and may on occasion have a better prognosis than their luminal cell 
derived counterparts17. But, identifying the legacy of basal-transformed cells presents 
difficulties and limits its clinical usefulness. 
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2.3.3 HER2 prostate cancers 
Given the similarities between prostate and breast cancer it is unsurprising that the 
HER2 oncogene has demonstrated an association with outcome in CaP. HER2 
overexpression has been found in approximately 20% of localised, untreated prostate 
cancers, and this rises to over 60% in metastatic disease and those cancers treated 
with ADT, although there is significant variation between studies, based on definition 
of ‘overexpression’ and also the assay used 65. Increased expression of HER2 in 
prostate cancer has been associated with higher Gleason grade, cancer stage and rate 
of proliferation (as demonstrated by the Ki67 index)66 and also poorer outcome than 
those tumours that express lower levels67. However, anti HER2 antibodies such as 
trastuzumab (Herceptin) that have proven extremely effective in HER2-positive breast 
cancer have not shown any clinical efficacy in prostate cancer. Interestingly 
trastuzumab is most effective in breast cancers in which HER2 overexpression is 
mediated by gene amplification. In prostate cancer, while HER2 expression is 
upregulated, gene amplification is uncommon, and thus the target may not be as 
important in this disease68. 
 
In summary, stratification of prostate cancer based on similar principles to that used 
for the molecular classification of breast cancer may be conceptually possible for the 
luminal and basal classes, but they do not represent the full heterogeneity seen in 
prostate cancer disease and its progression. Based on current academic knowledge and 
the development of breast cancer therapy, future clinical management of prostate 
cancer is going to require an individualised approach built on assessment of cell 
signalling biomarkers that inform about cell functional activity. 
  
28 
 
2.4 Patient cohort and clinical context 
The identification of molecular pathways and their significance in prostate cancer is 
made difficult due to the clinical course of the disease. CaP has a long latent phase 
where the patient is entirely asymptomatic and even patients who present late with 
metastases at diagnosis have an extended life expectancy (for example the median 
survival for patients with metastases in the recent Stampede study was 42 months69).  
 
Patients diagnosed with organ confined disease can expect to be cured in the majority 
of cases, be it surgically or using radiotherapy, and those with disease recurrence after 
attempted curative treatment are likely to live many years and indeed may die of 
another condition before their prostate cancer becomes an issue. The indolent course 
of disease progression means that interventions may not demonstrate efficacy for 
many years after they are used as it often takes ten to fifteen years for survival curves 
to start to separate, as has been demonstrated in many seminal papers looking at 
cancer outcomes post radical treatment70. This then leads to further difficulties with 
interpretation of the clinical relevance of these results as often in the intervening years 
clinical practice has changed and they are no longer carried out in the same way. 
 
The patient cohort examined in the study reported upon herein is unusual in that it has 
an extended period of clinical follow up – over 13 years – which makes it a powerful 
tool in the investigation of prostate cancer, particularly using high throughput 
immunohistochemical techniques that can interrogate multiple protein biomarkers in a 
relatively short period of time. The presence or absence of these markers can be 
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recorded, their levels of expression quantified and then associations with subsequent 
clinical outcome looked for. 
 
Patients in our research cohort were diagnosed with CaP between 1999 and 2001 and 
were being managed according to local best practice at that time. Patients were asked 
if they would allow their tissue to be used for research purposes, and if in agreement 
were included in the study. These were consecutive, non-selected patients. Initial 
diagnosis was made from tissue taken from either prostate needle core biopsy or 
trans-urethral resection of prostate (TURP) specimens. More detail can be found in 
section 3.2. 
 
The majority of patients in this cohort were diagnosed with prostate cancer from 
tissue taken during TURP, a surgical procedure that is done to relieve urinary 
obstruction by an enlarged prostate. This procedure is not intended to detect or treat 
cancer and does not reflect modern diagnostic practice. In the last 10 to 15 years the 
use of opportunistic PSA screening has dramatically increased the number of men 
investigated for prostate cancer and the standard of care was a trans-rectal biopsy of 
the prostate followed by staging investigations (such as MRI pelvis and bone scan) if 
cancer was detected. More recently the diagnostic pathway has begun to shift again, 
with increasing use of multi-parametric MRI and targeted trans-perineal biopsies of 
the prostate. This has led to a change in the proportion of patients diagnosed with 
various stages of prostate cancer. In the last decade the majority of prostate cancer 
was initially detected in its very early stages (i.e. organ confined).  
 
  
30 
Multi-parametric MRI has been shown to be extremely accurate at predicting the 
presence of high risk and intermediate risk (Gleason primary pattern 4) disease, and 
increasingly is being used to direct prostate biopsies and in the recent PROMIS trial 
demonstrated a corresponding increase in the diagnostic accuracy of targeted 
biopsies4. While MRI certainly provides excellent staging information and can be 
useful in operative planning, and may have a role in preventing unnecessary biopsies 
it is not yet accurate enough to replace biopsies when a diagnosis is required and 
should therefore be viewed as an adjunct to diagnosis rather than as a stand-alone tool. 
 
This shift in detection has led to criticisms of many studies carried out in the ‘pre-
screen detected’ era on the basis that they are no longer reflective of current practice. 
While the proportion of patients now diagnosed with CaP by TURP is now small they 
do however represent a group of patients that need addressing. Current European 
Association of Urology guidelines suggest treating TURP-detected CaP in a similar 
fashion to biopsy-detected cancer and as most are asymptomatic and have a low PSA 
and Gleason grade they are likely to be managed by active surveillance – i.e. have no 
treatment unless the clinical situation changes. This means our cohort is still relevant 
as the majority of our patients were only treated with hormones when they became 
symptomatic. 
 
As described earlier, a key factor in assessing the significance of a patient’s prostate 
cancer is the Gleason score (Figure 1). The Gleason score is based on a histological 
examination of prostate tissue. The most common architectural pattern is identified 
and graded on a scale of 1 to 5 and then the second most common architectural pattern 
is similarly graded. The two scores are then added together giving a total out of 10.  
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While the fundamentals of this classification remain the same there have been some 
changes in the way cells are assigned to a particular grade category and this has 
implications for our cohort. Our patients’ tissue was collected between 1999 and 2002 
and was graded based on the Gleason score at the time. However, in 2005 the 
International Society of Urological Pathology (ISUP; Tables 1 and 2) made some 
changes that particularly affected low and intermediate grading71. For example, 
modifications included taking into account grading of variants of prostate carcinoma 
and unusual morphologies, such as ductal adenocarcinoma, considered as Gleason 
grade 4 (GS 8 if pure), pseudohyperplastic variant, graded as Gleason score 3+3=6 
and mucinous fibroplasia which is subtracted and gland graded (mostly Grade 3). 
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Figure 1: An example of the histological patterns used to assign Gleason Score 
(Image taken from ‘Commons.WikiMedia.org’ with permission to share and 
reproduce) 
 
 
 
Interestingly, very recently the ISUP have altered the system again with slight 
variations as to how cell architecture should be classified, but more importantly a 
significant difference in how the overall Gleason score is presented72 (Table 3). For 
some years, Gleason score 6 has been the lowest total score that is considered a true 
prostate cancer and is therefore the least significant and is unlikely to cause patient 
morbidity and mortality. However, there was a gradual appreciation that patients were 
unduly worried by this system, as they perceived their score was 6/10 and was 
therefore a potentially dangerous cancer. The new system assigns the various Gleason 
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Score combinations into 5 grade categories from 1 to 5, with 1 the least significant 
and 5 the worst (Table 3).  
 
Table 1: Changes in Gleason patterns proposed at the ISUP meeting 200573 
 
Gleason		
Pattern	
ISUP	modified	Gleason	grading		changes	compared	to	
conventional	Gleason	grading	
1	 A	Gleason	score	of	1+1=2	should	not	be	diagnosed	regardless	of	type	of	specimen.	Extremely	rare	exceptions	
2	 A	Gleason	score	of	2+2=4	should	be	diagnosed	rarely,	if	ever.	Glands	should	not	infiltrate	between	non-neoplastic	prostate	acini	
3	 Typical	pattern	3	consists	of	circumscribed,	variably	sized	but	often	small	individual	glands	that	may	infiltrate	among	non-neoplastic	acini	
4	 3	main	variants	of	pattern	4:	
• Most	cribriform	patterns	should	be	pattern	4.	Subtle	features	such	as	slight	irregularity	of	the	outer	border	of	glands	should	be	sufficient	to	move	the	glands	from	pattern	3	to	pattern	4.	
• Fused	Glands	
• Incomplete	or	poorly	formed	glands	
5	 Comedocarcinoma	with	central	necrosis	
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Table 2: Changes in the reporting of Gleason grading proposed at the ISUP meeting 
200574 
 
Specimen		 ISUP	modified	Gleason	grading	changes	to	conventional	Gleason	Grading	
Biopsies	 The	Gleason	score	of	tumours	on	biopsy	with	tertiary	higher	grade	should	include	the	tertiary	pattern	and	not	be	listed	with	primary	and	secondary	patterns	with	a	note	relating	to	tertiary	pattern	
Biopsies	 A	Gleason	score	should	be	reported	for	each	individual	core	or	container	
Biopsies	 The	highest	grade	would	typically	be	the	one	selected	by	the	clinician	as	the	grade	of	the	entire	case.	One	also	has	the	option	to	give	an	overall	score	at	the	end	of	the	case,	in	addition	to	individual	scores	
Prostatectomy	
Specimen	
A	separate	Gleason	score	should	be	assigned	to	each	dominant	tumour	nodule	
Prostatectomy	
Specimen	
Tertiary	patterns	of	higher	grade	should	not	be	included	in	the	Gleason	score	but	rather	be	mentioned	separately	
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Table 3: Changes in the reporting of Gleason grade groups proposed at the ISUP 
meeting 201472 
 
Grade Group 1 
(3+3) 
Only individual discrete well-formed glands 
Grade Group 2 
(3+4) 
Predominantly well-formed glands with lesser component 
of poorly- formed/fused/cribriform glands 
Grade Group 3 
(4+3) 
Predominantly poorly formed/fused/cribriform glands with 
lesser component of well-formed glands 
Grade Group 4 
(4+4 / 3+5 / 5+3) 
Only poorly-formed/fused/cribriform glands or 
Predominantly mix of well-formed and lack of glands 
Grade Group 5 
(4+5 / 5+4 / 5+5) 
Lack gland formation (or with necrosis) with or w/o poorly 
formed/fused/cribriform glands 
 
As can be seen below in the results section, our main analysis was based on the pre-
ISUP 2005 Gleason classification. After discussion with the editorial office at the 
British Journal of Cancer (where our data relating to the markers Ki67 and DLX2 
have been published75) it was felt to be more clinically relevant to re-score our cohort 
using ISUP 2005, as this is the most widespread classification used in contemporary 
day-to-day clinical practice. We therefore reviewed our histological specimens and 
reassessed the relevant data. For comparison we include pre- and post-ISUP 2005 
results for the markers Ki67 and DLX2. 
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2.5 Artificial Neural Networks 
Artificial neural networks (ANNs) are a form of machine learning from the field of 
artificial intelligence with proven pattern recognition capabilities and have been 
utilized in many areas of bioinformatics76. ANNs have been widely employed in the 
identification and stratification of molecular biomarkers77,78 and are inspired by the 
way organic systems learn and processes complex information. ANNs have the ability 
to handle complex (non-linear) features within data in order to generalise and predict 
outcomes accurately in future cases76. 
 
ANNs are essentially information processing tools that utilise methods observed in 
biological systems such as the human brain. The networks are made up of a large 
number of interconnected processing elements that work in parallel to produce an 
output, based on input data chosen by the system operator (Figure 2). These 
processing elements make decisions based on a simple set of rules, and the outputs 
contribute to the rest of the network elements which then make further decisions with 
the entire system acting in a gestalt way allowing extremely complex data analysis 
and pattern recognition.  
 
In general, ANNs utilise 3 layers: an input layer, a series of ‘hidden’ interconnected 
nodes and an output layer. The difference between conventional computational 
algorithms and ANN systems is that ANNs have the ability to self-correct if the 
outcome is not sufficiently close to that required by the user, i.e. they can learn. This 
learning process actually takes place by altering the strength of connection between 
certain nodes involved in the computational pathway, so if a connection leads to a 
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correct result then the strength or likelihood of this connection being used again 
increases. 
 
Figure 2: Diagrammatic representation of the concepts of an ANN (image taken from 
www.texample.net with permission) 
 
 
 
ANNs are now used widely in the field of medical bioinfomatics and have been used 
successfully in the field of prostate cancer research over the last 10 to 20 years, 
although not on a large scale. For example, ANN techniques were shown to 
accurately predict trans-rectal prostate cancer biopsy outcome using a ‘feed-forward’ 
network with the input variables ‘PSA, DRE, age, and percentage of free PSA’ as 
early as 200379. However, over the last few years a growing realisation and awareness 
of the technique has led to increased interest, not least because of the vast complexity 
of data now available for analysis due to high throughput techniques such as gene 
expression arrays and the desire to find reliable biomarkers that can accurately stage 
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the disease, with prognostic utility, without necessarily having to carry out invasive 
procedures80. 
 
2.6 Aims and objectives 
The aim of this research project was to identify a panel of prostate cancer associated 
protein biomarkers that can reliably predict patient outcome at the point of diagnosis. 
Outcome in this context is the likelihood of a patient subsequently developing 
metastatic disease or dying of prostate cancer. This will allow patients to be more 
accurately ‘risk stratified’ into groups, subsequently helping to inform and guide 
treatment decisions. This will improve outcomes in those that need radical 
intervention and minimise the number of patients undergoing unnecessary treatment, 
thereby avoiding inherent complications. 
 
Candidate biomarkers were identified using two approaches. The first was the use of 
bioinfomatic techniques, in particular artificial neural network analysis of publically 
available CaP gene expression arrays, carried out by Professor Graham Ball 
(Nottingham Trent University). The second was based on a comprehensive review of 
the current literature examining the links between the molecular classification of 
prostate cancer and subsequent clinical outcomes.  
 
A tissue microarray (TMA) has already been constructed from archival wax-
embedded prostate cancer taken from 365 patients (fully consented and ethically 
approved) between 1999 and 2002. A major component of this project was populating 
a database of patient outcomes over the following 12 years for this cohort. This 
involved reviewing the medical records of every patient and recording pathological, 
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treatment and outcome data. This data allowed eventual comparison of biomarker 
panels with clinical risk groupings. 
 
Statistical analysis was carried out to look for associations between biomarker 
expression and clinico-pathological variables and their ability to predict prostate 
specific survival, tumour recurrence, metastasis development, and treatment failure.  
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3.0 Materials and Methods 
3.1 Overview 
Candidate biomarkers associated with metastases and outcome in prostate cancer were 
selected using the techniques described in detail below. A tissue microarray (TMA) of 
patients diagnosed with CaP between 1999 and 2001 has recently been created by Dr 
Des Powe (DGP), Histopathology Department, NUH, comprising tumour and 
adjacent samples of tissue from each patient. These were then immunostained for 
protein expression of each marker, with markers being selected using a bioinformatic 
approach and additional literature search. Staining was quantified and independently 
scored by WG & DGP, with levels of agreement checked to ensure consistent results.  
 
The North West 7 Research Ethics Committee approved use of the tissue samples for 
this study – Greater Manchester Central REC number 10/H1008/72. 
 
Patient outcome data was collated in a spreadsheet (Microsoft Excel) with multiple 
parameters recorded, as described below. This data was used to determine the clinical 
progression of the disease and drive subsequent statistical analysis and risk 
stratification. 
 
3.2  Patient cohort and data collection 
365 Patients diagnosed with CaP between 1999 and 2001 were incorporated into the 
TMA. These were consecutive non-selected patients and all underwent contemporary 
‘best-practice’ treatment at Nottingham City Hospital, UK. Initial histological cancer 
diagnosis was made using tissue obtained by prostate needle core biopsy, transurethral 
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resection of prostate (TURP) or radical prostatectomy (RP) specimens and cohort 
patient characteristics can be seen in Table 4 below.  
 
Multiple data points were recorded for each patient (Table 5), after initial discussions 
between clinicians and research scientists to determine which factors were required to 
demonstrate variation in patient demographics, initial histological diagnosis, treatment 
modalities and clinical outcome. 
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Table 4: Clinical characteristics of prostate cancer patients incorporated in the TMA, 
including method of tissue extraction, PSA at diagnosis, Gleason score, D’Amico 
score, androgen deprivation treatment status, metastatic status and mortality. 
Clinical Variable	  Number of patients (%)	
Surgical procedure	 TURP	 279 (76%)	
 Prostatectomy	 26 (7%)	
 Biopsy	 54 (15%)	
 Not recorded	 6 (2%)	
   
PSA (ng/ml) at diagnosis	 <4	 34 (9%)	
 >4	 237 (65%)	
 Not recorded	 94 (26%)	
   
Gleason Score	 ≤7	 141 (39%)	
 ≥8	 156 (43%)	
 Not recorded	 68 (19%)	
   
D’Amico risk	 Low	 54 (15%)	
 Intermediate	 33 (9%)	
 High	 202 (55%)	
 Unclear	 76 (21%)	
   
Antigen deprivation therapy	 Yes	 197 (54%)	
 No	 87 (24%)	
 Unclear	 81 (22%)	
   
Castration resistant	 Yes	 127 (65% of those rendered 
castrate)	
 No	 70 (35% of those rendered 
castrate)	
   
Metastasis at diagnosis	 Yes	 44 (12%)	
 No	 257 (70%)	
 Not recorded	 64 (18%)	
   
Subsequent metastases (in those 
patients without metastases at 
diagnosis)	
Yes	 85 (23%)	
 No	 167 (46%)	
 Not recorded 69 (19%) 
   
Death due to prostate cancer	 Yes	 134 (37%)	
 No	 92 (25%)	
 Unknown	 87 (24%)	
 Still alive	 52 (14%)	
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Table 5: Patient and clinical factors recorded in the patient database 
Racial origin	 Date of 
Diagnosis	
Initial PSA	 Initial DRE	 Use of 5aRI	 Mode of 
tissue 
diagnosis	
Gleason1 	 Gleason2	 Overall 
Gleason score	
Initial 
D’Amico 
risk	
Alternate 
histology 
Extra 
prostatic 
invasion  
Perineural 
invasion 
Vascular 
invasion 
Nodes 
negative 
Negative 
resection 
margins 
% Cancer Bone mets 
at diagnosis 
Radical 
prostatectomy 
histology 
Active 
surveillance 
Radiotherapy 
(DXT) 
Date of 
DXT 
Recurrence 
after DXT 
Subsequent 
mets 
Date of mets Location of 
mets 
Months to 
mets from 
diagnosis 
Chemo 1st Androgen 
deprivation 
therapy (ADT) 
Date of 1st 
ADT 
2nd ADT Date of 2nd 
ADT 
3rd ADT 
 
Date of 3rd 
ADT 
Death Date of 
death 
CaP related 
death 
Months to 
all cause 
death 
Months to 
castrate 
resistance 
Months to 
CaP specific 
death 
Other cause of 
death 
B-Blocker Date of 
initiation of 
B-blocker 
Comments PSA 
surveillance 
values 
Dates of 
PSA  
    
 
Patient data were obtained from a combination of review of paper-based medical 
notes, and Nottingham University Hospitals’ computer-based results system ‘NOTIS’. 
All data were recorded in a spreadsheet (Microsoft Excel) and all patient identifiers 
were removed other than a derived ‘patient analysis number’ used to ensure that 
multiple TMA cores taken from a single patient could be matched to the 
corresponding clinical data. 
 
3.3  Tissue microarray construction and layout 
A TMA was constructed using archival wax-embedded TURP and radical 
prostatectomy samples sourced via the Nottingham Health Science BioBank. 
Histology sections were reviewed by a pathologist (Dr Geoffrey Hulman, GH) and 
0.6mm diameter donor cores were sampled from at least two different tumour regions 
per patient using an automated TMA Grand Master instrument (3DHistech Ltd, 
Hungary) and placed in paraffin blocks. Each block accommodates 100 cores, with 
the majority of patients being represented by at least 2 cores, and some up to 6 cores. 
Each block was arranged in a grid pattern from A1 to J10, and the blocks were 
serially numbered. Each core was assigned a unique ‘NPN’ number (starting at ‘2000’ 
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for core A1 in the first block and continuing in sequence to 2968 for core E10 in the 
final block) that allows subsequent biomarker scores to be linked to a particular tissue 
sample from a particular patient, without compromising patient personal data. All 
TMA tissue sections for IHC were cut at a thickness of 4µm on a microtome. The 
pathology of constituent cores in the finished TMA was confirmed by GH. 
 
3.4 Biomarker selection  
3.4.1 Artificial neural network analysis 
Artificial neural analysis of publically available prostate cancer cDNA gene 
expression arrays (U133A – data source GSE8218, U133Plus2.0 – data source 
GSE17951 and U95Av2 – data source GSE1431)81 was carried out by Professor 
Graham Ball (Nottingham Trent University), looking at markers that confer an 
increased risk of progression and metastases. The ANN model was reiterated 50 times 
with random sampling and the average mean square error of a test subset for each 
input variable was considered to determine the predictive capability for metastasis 
class. 
 
The top 10 genes ranked for association with metastasis development are included in 
Table 6. Four of these had commercially available antibodies (AMACR (Racemase), 
DLX2, PAICS and MYO6) directed against proteins and were validated using 
immunohistochemical staining of the Nottingham prostate TMA.  
 
3.4.2 Literature search 
For comparison, a curated literature search was performed by Mr Will Green and Dr 
Des Powe to identify biomarkers previously proposed for predicting disease-specific 
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survival (DSS).  DSS is clearly an outcome measure of extreme importance when 
investigating cancer biomarkers and we felt it was important to include this as one of 
the key aims of the study was to identify biomarkers with practical clinical utility. The 
search was performed using ‘Web of Science’ and the following terms: 
1) ‘Review’, ‘genomic studies’, ‘prostate cancer’ – this search returned 167 results, of 
which 19 papers were appropriate for full review. 
2) ‘Prostate cancer’, ‘transcriptome’, ‘classification’ – 2 results, both fully reviewed. 
3) ‘Prostate cancer’, ‘cluster analysis’, ‘stratification’ – 8 results, of which 2 papers were 
appropriate for full review 
4) ‘Prostate cancer’, ‘cluster analysis’ – 955 results, of which 22 papers were 
appropriate for full review. 
The literature search highlighted 5 further candidate biomarkers that were reported to 
be associated with prostate cancer associated survival. These included the 
proliferation marker Ki67, the tumour suppressor gene p53, the basal cell marker 
CK5/6, the proposed stem cell-like markers C-MET and integrin alpha2 and the gene 
fusion product TMPRSS-ERG. Table 6 shows the antibodies used to stain the 
Nottingham prostate TMA. 
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Table 6: ANN ranked gene list showing association with prostate cancer metastasis  
Rank Gene accession number Gene name Gene Product 
(protein) 
1	 AK022765.1	 AMACR
 	
Alpha-methylacyl-CoA racemase 
2	 AI796120	 AMACR
 	
Alpha-methylacyl-CoA racemase 
3	 AF047020.1	 AMACR
 	
Alpha-methylacyl-CoA racemase 
4	 NM_004405.2	 DLX2	 Distal-less homeo box 2 
5	  PCA3	 Prostate cancer antigen 3 
6	 NM_012485.1	 HMMR 	 Hyaluronan-mediated motility receptor 
(RHAMM or CD168) 
7	 U90236.2	 MYO6	 Myosin VI 
8	 NM_017636.1	 FLJ20041	 Hypothetical protein FLJ20041 
Alias: TRPM4B 
9	 BF511718 	 RHO7	 GTP-binding protein Rho7 
Alias: RND2 
11	 NM_006452.1	 ADE2H1	 Multifunctional polypeptide similar to 
SAICAR synthetase and AIR carboxylase 
Alias: PAICS 
12	 NM_002570.1	 PACE4	 Paired basic amino acid cleaving system 
 
13	 NM_004503.1	 HOXC6 	 Homeo box C6 
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Table 7: Antibodies used for immunohistochemical staining of the Nottingham 
prostate TMA. (Microwave antigen retrieval - MAR) 
Gene name	 Gene Product	
(protein)	
Manufacturer/clone/+ve 
Control	
Dilution/MAR	
AMACR 	 Alpha-methylacyl-CoA 
racemase 
Dako M3616 
Clone 13H4 
Control – Human Breast Tissue  
1:200/Citrate 
DLX2	 Distal-less homeo box 2 Abcam 
Ab18188 
Polyclonal 
Control – Mouse Brain 
1:1500/Citrate 
MYO6	 Myosin VI Abcam	
ab170522 
Polyclonal 
Control – Human Breast Tissue 
1:300/Citrate 
PAICS/ADE2H 	 Multifunctional 
polypeptide similar to 
SAICAR synthetase and 
AIR carboxylase 
Alias: PAICS 
Abcam 
ab174685 
Polyclonal 
Control – Human Breast Tissue 
1:1000/Citrate 
Ki67	 Proliferation marker  Leica 	
NCL-L-MM1 
Clone MM1 
Control – Colorectal Tissue	
1:25/Citrate 
P53	 Tumour suppressor gene Leica  
ICL-L-p53-DO 
Clone DO-7 
Control – Human Breast Tissue 
1:50/Citrate 
CK5/6	 Basal-like epithelial cell 
marker 
Dako  
M7237 
Clone D5/16 B4 
Control – Tonsillar Tissue 
1:50/Citrate 
C-MET	 Receptor for hepatocyte 
growth factor  
Abcam  
ab51067 
Clone EP1454Y 
Control – Human Breast Tissue 
1:400/Citrate 
Integrin alpha2	 Cell adhesion molecule Abcam 
Ab133557 
Clone EPR5788 
Control – Human Breast Tissue 
1:300/Citrate 
 
 
3.5 Immunohistochemistry (IHC) 
Optimal antibody dilutions and antigen retrieval conditions were initially performed 
using positive and negative control tissues at dilutions suggested by the antibody 
suppliers. Positive and negative samples were then examined by Dr Des Powe (DP) 
and Mr Will Green (WG) and an assessment made of whether it was possible to 
clearly discriminate between the control samples at these dilutions. In samples that 
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were not clearly demarcated the dilutions were titrated as appropriate. 4µm sections 
from each TMA block were mounted on Dako REALTM Capillary Gap Microscope 
Slides, 75 µm (Grey), S2024 (Dako UK Ltd.). After initial optimisation each set of 
TMA sections representing the entire clinical cohort underwent IHC according to the 
protocol developed by Dr TMA Abdel-Fatah82 (Clinical Oncology Department, 
Nottingham City Hospital), as described below.  
 
The sections were dewaxed by being heated at 60°C and then sequentially immersed 
in xylene, IMS and dH20 using an autostainer (Leica Autostainer XL). The sections 
then underwent microwave antigen retrieval for 20 minutes in an antigen retrieval 
buffer (10mM solution of sodium citrate, pH6). Slides were then loaded into a 
sequenza reservoir and underwent exposure to serial reagents using a Novolink kit. 
First, they were exposed to a peroxidase block for 5 minutes, then a protein block for 
5 minutes. They were then incubated for 1 hour at room temperature with the relevant 
antibody in each experiment (see Table 7 for antibodies and concentrations). After 
incubation, slides were then exposed to the post primary block, a polymer, DAB 
working solution and finally haematoxylin. Slides were washed with Tris-buffered 
saline (TBS) between each stage. Slides were then dehydrated in the autostainer using 
industrial methylated spirits IMS and xylene and mounted in DPX mounting medium. 
 
Immunostained TMA sections were assessed to determine the appropriate scoring 
technique for quantifying protein expression levels. Sections were independently 
scored (WG, DGP) without knowledge of pathology grade. Staining thresholds used 
for dichotomous categorisation were chosen using the software program X-tile, or by 
those given in previously published studies.  
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H-scoring was used for Ki67 (>110 = positive), P53 nuclear (>90 = positive), 
AMACR (>30 = positive) and DLX2 (>10 = positive). Categorical scoring was used 
for PAICS and Integrin alpha (0=absent, 1=weak, 2=strong; 2 considered positive), 
CMET (0=absent, 1=weak, 2 strong; 1 and 2 considered positive), MYO6 (0=absent, 
1=weak, 2=moderate, 3=strong; 2 and 3 considered positive). Presence/absence was 
used for P53 cytoplasmic, CMET membranous, Integrin alpha membranous, and CK 
5/6. 
 
We used REMARK (REporting recommendations for tumour MARKer prognostic 
studies) guidelines for reporting on prognostic biomarkers in the whole patient series. 
REMARK guidelines are an internationally recognised set of parameters developed to 
ensure a robust standard of study design, pre-planned hypotheses, patient and 
specimen characteristics, assay methods, and statistical analysis methods83.   
 
The proportion of patients with scorable tissue cores was less than the total number of 
patients originally incorporated in the TMA due to detachment of cores during 
processing and insufficient cancer tissue. Missing data were assessed for randomness 
using a Little’s test and Wilcoxon-Mann-Whitney test, both at 95% confidence level. 
We failed to reject the null hypothesis of data being missing completely at random 
(p>0.05). Table 8 demonstrates the number of patients that could be scored each 
individual marker. No marker had a score reflecting the whole patient cohort as some 
core samples were lost in processing and others contained no cancer cells in the 
microtome section analysed. 
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Table 8: The number of patients within the prostate cancer cohort that were 
dichotomously categorised for each biomarker 
 
3.6 Statistical analysis 
Statistical analysis was performed using SPSS (Version 21; IBM, US) applied to 
verified cancer samples.  Pearson Chi-square tests were performed to assess 
biomarker associations with clinicopathological variables including initial PSA, 
Gleason score and initial risk (D’Amico). Kaplan-Meier plots with log-rank tests were 
used to model biomarker associations with disease-specific survival (DSS), time to 
metastasis development and time to castrate resistance. Biomarkers that showed an 
association with DSS or metastasis were included in a multivariate Cox proportional 
hazards regression model to assess the additional prognostic value to the PSA and 
Gleason score. The significance level used was P<0.05.  
 
  
Biomarker Number of cancer 
patients scored 
Percentage positive Percentage 
negative 
Ki67	 182	 6.6	 93.4	
P53 Nuclear	 223	 10.3	 89.7	
PAICS	 175	 80.6	 19.4	
MYO 6	 219	 48.4	 51.6	
CMET cytoplasmic	 193	 80.8	 19.2	
INTa cytoplasmic	 203	 34.0	 66.0	
Racemase	 214	 72.9	 27.1	
CK 5/6	 221	 28.5	 71.5	
DLX2	 209	 72.7	 27.3	
  
51 
4.0 Results – Initial analysis of all markers with pre ISUP 2005 histology 
Univariate associations between candidate biomarkers and clinicopathological 
variables are shown in Tables 9-12. Multivariate Kaplan-Meier models showing the 
associations between biomarkers with DSS, time to metastasis and castrate resistance 
are shown in Table 13. Example biomarker staining patterns are shown in Figure 5. 
 
Table 9 Association of Racemase, DLX2 and MYO6 with clinical pathology 
variables. Significant p-values are shown in bold. 
 
  Racemase 
negative  
Racemase 
positive 
 DLX2 
negative 
DLX2 
positive 
 MYO6 
negative 
MYO6 
positive 
 
Clinical 
Variable 
 Number 
(%) 
 
Number 
(%) 
 
Chi-
square 
(p-value) 
Number 
(%) 
 
Number 
(%) 
 
Chi-
square 
(p-value) 
Number 
(%) 
 
Number 
(%) 
 
Chi-
square 
(p-value) 
PSA 
(ng/ml) at 
diagnosis 
<4 3 
(27.3%) 
8 
(72.7%) 
0.007 
(p=0.93) 
2
  
(20%)
  
8
  
(80%)
  
0.458 
(p=0.499) 
8 
(66.7%) 
4 
(33.3%) 
1.649 
(p=0.969) 
 >4 40 
(26.1%) 
113 
(73%) 
 132
  
(30.1%)
  
187
  
(69.9%)
  
 74 
(47.4%) 
82 
(52.6%) 
 
           
Gleason 
Score 
≤7 22 
(23.2%) 
73 
(76.8%) 
1.409 
(0.235) 
22
  
(25.3%)
  
65
  
(74.7%)
  
0.483 
(p=0.487) 
43 
(43%) 
57 
(57%) 
6.808 
(p=009) 
 ≥8 31 
(30.7%) 
70 
(69.3%) 
 31
  
(29.8%)
  
73
  
(70.2%)
  
 62 
(61.4%) 
39 
(38.6) 
 
           
D’Amico 
risk 
Low 8 
(33.3%) 
16 
(66.7%) 
6.114 
(p=0.04) 
3
  
(15%)
  
 
17
  
(85%)
  
 
2.102 
(p=0.350) 
16 
(66.7%) 
8 
(33%) 
14.667 
(p=0.001) 
 Intermediate 1 
(5%) 
19 
(95%) 
 4
  
(23.5%)
  
13
  
(76.5%)
  
 2 
(11.1%) 
16 
(88.9%) 
 
 High 40 
(31%) 
89 
(69%) 
 41
  
(29.9%)
  
96
  
(70.1%)
  
 75 
(55.1%) 
61 
(44.9%) 
 
           
Antigen 
deprivation 
therapy 
(ADT) 
Yes 39 
(28.3%) 
99 
(71.7%) 
0.56 
(p=0.813) 
41
  
(29.1%)
  
100
  
(70.9%)
  
1.165 
(p=0.280) 
73 
(51.8%) 
68 
(48.2%) 
0.007 
(p=0.935) 
 No 10 
(26.3%) 
28 
(73.7%) 
 7
  
(20%)
  
28
  
(80%)
  
 21 
(52.5%) 
19 
(47.5%) 
 
           
Castration 
resistant 
Yes 24 
(27%) 
65 
(73%) 
0.145 
(p=0.703) 
29
  
(31.2%)
  
64
  
(68.8%)
  
1.891 
(p=0.169) 
49 
(54.4%) 
41 
(45.6%) 
0.206 
(p=0.650) 
 No 26 
(29.5%) 
62 
(70.5%) 
 18
  
(22%)
  
64
  
(78%)
  
 47 
(51.1%) 
45 
(48.9%) 
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Table 10 Association of PAICS, Ki67 and P53 with clinical pathology variables. 
Significant p-values are shown in bold. 
  PAICS 
negative  
PAICS 
positive 
 Ki67 
negative 
Ki67 
positive 
 P53 
negative 
P53 
positive 
 
Clinical 
Variable 
 Number 
(%) 
 
Number 
(%) 
 
Chi-square 
(p-value) 
Number 
(%) 
 
Number 
(%) 
 
Chi-square 
(p-value) 
Number 
(%) 
 
Number 
(%) 
 
Chi-square 
(p-value) 
PSA (ng/ml) at 
diagnosis 
<4 3 
(33.3%) 
6 
(66.6%) 
2.620 
(p=0.106) 
9 
(100%) 
0 
(0%) 
0.645 
(p=0.422) 
10 
(83.3%) 
2 
(16.7%) 
0.289 
(p=0.591) 
 >4 17 
(13.5%) 
109 
(86.5%) 
 125 
(93.3%) 
9 
(6.7%) 
 139 
(88.5%) 
18 
(11.5%) 
 
           
Gleason Score ≤7 17 
(21.8%) 
61 
(78.2%) 
0.857 
(p=0.355) 
84 
(96.6%) 
3 
(3.4%) 
2.690 
(p=0.101) 
95 
(92.2%) 
8 
(7.8%) 
2.040 
(p=0.153) 
 ≥8 13 
(16.0%) 
68 
(84.0%) 
 75 
(90.4%) 
8 
(9.6%) 
 86 
(86.0%) 
14 
(14.0%) 
 
           
D’Amico risk Low 4 
(23.5%) 
13 
(76.5%) 
0.460 
(p=0.795) 
20 
(95.2%) 
1 
(4.8%) 
1.493 
(p=0.474) 
25 
(92.6%) 
2 
(7.4%) 
0.514 
(p=0.773) 
 Intermediate 3 
(18.8%) 
13 
(81.2%) 
 18 
(100%) 
0 
(0 %) 
 18 
(90.0%) 
2 
(10.0%) 
 
 High 18 
(16.8%) 
89 
(83.2%) 
 103 
(92.8%) 
8 
(7.2%) 
 117 
(88.0%) 
16 
(12.0%) 
 
           
Antigen 
deprivation 
therapy (ADT) 
Yes 20 
(17.7%) 
9 
(82.3%) 
0.185 
(p=0.667) 
108 
(92.3%) 
9 
(7.7%) 
2.781 
(p=0.095) 
122 
(87.1%) 
18 
(12.9%) 
2.276 
(p=0.131) 
 No 4 
(14.3%) 
24 
(85.7%) 
 34 
(100%) 
0 
(0%) 
 41 
(95.3%) 
2 
(4.7%) 
 
           
Castration 
resistant 
Yes 13 
(18.6%) 
57 
(81.4%) 
0.201 
(p=0.654) 
69 
(90.8%) 
7 
(9.2%) 
1.768 
(p=0.184) 
79 
(86.8%) 
12 
(13.2%) 
0.998 
(p=0.318) 
 No 11 
(15.7%) 
59 
(84.3%) 
 74 
(96.1%) 
3 
(3.9%) 
 85 
(91.4%) 
8 
(8.6%) 
 
 
 
Table 11 Association of CK5/6, C-MET and Integrin alpha2 with clinical pathology 
variables. Significant p-values are shown in bold. 
  CK5/6 
negative 
CK5/6 
positive 
 C-MET 
negative 
C-MET 
positive 
 Integrin 
α2 
negative 
Integrin 
α2 
positive 
 
Clinical 
Variable 
 Number 
(%) 
 
Number 
(%) 
 
Chi-square 
(p-value) 
Number 
(%) 
 
Number 
(%) 
 
Chi-square 
(p-value) 
Number 
(%) 
 
Number 
(%) 
 
Chi-square 
(p-value) 
PSA (ng/ml) at 
diagnosis 
<4 4 
(36.4%) 
7 
(63.6%) 
6.859 
(p=0.009) 
3 
(27.3%) 
8 
(72.7%) 
0.316 
(p=.574) 
6 
(60.0%) 
4 
(40.0%) 
0.243 
(p=0.622) 
 >4 116 
(73.4%) 
42 
(26.6%) 
 28 
(20.1%) 
111 
(79.9%) 
 100 
(67.6%) 
48 
(32.4%) 
 
           
Gleason Score ≤7 66 
(65.3%) 
35 
(34.7%) 
3.324 
(p=.068) 
17 
(19.1%) 
72 
(80.9%) 
0.352 
(p=0.553) 
53 
(59.6%) 
36 
(40.4%) 
2.598 
(p=0.107) 
 ≥8 77 
(77.0%) 
23 
(23.0%) 
 20 
(22.7%) 
68 
(77.3%) 
 68 
(70.8%) 
28 
(29.2%) 
 
           
D’Amico risk Low 15 
(60.0%) 
10 
(40.0%) 
6.179 
(p=0.046) 
7 
(31.8%) 
15 
(68.2%) 
6.513 
(p=0.039) 
9 
(45.0%) 
11 
(55.0%) 
5.034 
(p=0.081) 
 Intermediate 10 
(52.6%) 
9 
(47.4%) 
 0 
(0.0%) 
18 
(100.0%) 
 13 
(65.0%) 
7 
(35.0%) 
 
 High 101 
(75.9%) 
32 
(24.1%) 
 28 
(24.1%) 
88 
(75.9%) 
 88 
(70.4%) 
37 
(29.6%) 
 
           
Antigen 
deprivation 
therapy (ADT) 
Yes 102 
(73.4%) 
37 
(36.6%) 
1.303 
(p=0.254) 
27 
(22.3%) 
93 
(76.9%) 
0.320 
(p=0.852) 
90 
(67.7%) 
43 
(32.3%) 
0.727 
(p=0.394) 
 No 27 
(64.3%) 
15 
(35.7%) 
 8 
(21.6%) 
29 
(78.4%) 
 21 
(60.0%) 
14 
(40.0%) 
 
           
Castration 
resistant 
Yes 67 
(74.4%) 
23 
(25.6%) 
0.794 
(p=0.373) 
20 
(26.0%) 
56 
(72.7%) 
2.822 
(p=0.244) 
60 
(69.0%) 
27 
(31.0%) 
0.357 
(p=0.550) 
 No 63 
(68.5%) 
29 
(31.5%) 
 14 
(17.5%) 
66 
(82.5%) 
 53 
(64.6%) 
29 
(35.4%) 
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Table 12 Association of ERG2 with clinical pathology variables. Significant p-values 
are shown in bold. 
  ERG2 
Negative 
ERG2 positive  
Clinical Variable  Number 
% 
 
Number 
% 
 
Chi-square 
(p-value) 
PSA (ng/ml) at diagnosis <4 6 
(85.7%) 
1 
(14.3%) 
1.270 
(p=0.260) 
 >4 76 
(65.0%) 
41 
(35.0%) 
 
     
Gleason Score ≤7 45 
(67.2%) 
22 
(32.8%) 
0.046 
(p=0.831) 
 ≥8 53 
(68.8%) 
24 
(31.2%) 
 
     
D’Amico risk Low 11 
68.8% 
5 
31.2% 
0.012 
(p=0.994) 
 Intermediate 11 
68.8% 
5 
31.2% 
 
 High 65 
67.7% 
31 
32.3% 
 
     
Antigen deprivation therapy (ADT) Yes 67 
65.7% 
35 
34.3% 
0.871 
(p=0.351) 
 No 21 
75.0% 
7 
25.0% 
 
     
Castration resistant Yes 44 
(67.7%) 
21 
(32.3%) 
0.016 
(p=0.901) 
 No 44 
(66.7%) 
22 
(33.3%) 
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Table 13: Kaplan-Meier modelling was used to assess the association of biomarkers 
in predicting disease specific mortality, time to metastasis (months) and castrate 
resistance (months). Significant associations are shown in bold. 
 
 
  
Biomarker	 CaP specific 
mortality	
Time to metastasis	 Time to castrate 
resistance	
       
 χ2	 p-value	 χ2	 p-value	 χ2	 p-value	
       
       
Ki67	 5.069	 0.024	 4.822	 0.028	 4.838	 0.028	
       
p53 nuclear	 3.897	 0.048	 0.012	 0.914	 0.194	 0.659	
       
PAICS	 0.002	 0.966	 0.383	 0.536	 1.11	 0.292	
       
MYO6	 3.026	 0.082	 0.423	 0.515	 1.314	 0.252	
       
CMET cytoplasmic	 2.945	 0.086	 16.208	 0.00005	 2.023	 0.155	
       
INT-a cytoplasmic	 0.45	 0.502	 1.362	 0.243	 0.399	 0.528	
INT-a membranous	 0.044	 0.833	 0.13	 0.718	 2.262	 0.133	
       
Racemase	 0.705	 0.401	 2.974	 0.085	 0.213	 0.644	
       
CK5/6	 0.344	 0.558	 0.091	 0.762	 2.161	 0.142	
       
DLX2	 3.536	 0.06	 12.12	 0.0005	 1.182	 0.277	
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Figure 3: Examples of IHC staining 
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4.1 Single biomarkers 
Racemase (AMACR) 
• Increased cytoplasmic racemase expression showed positive association with 
initial D’Amico risk at diagnosis (χ2=6.114, p=0.047). 
• No association was seen between racemase expression and initial serum PSA, 
Gleason score, castrate resistance, metastasis development, CaP-specific 
survival (CaPSS) or overall survival (OS).   
 
DLX2 
• Increased nuclear DLX2 expression showed a positive association with 
metastasis development (χ2=12.12, p=0.0005), independently of PSA 
concentration and Gleason score using multivariate Cox regression analysis 
(HR=3.311, p=0.0002, 95%CI=1.756-6.241). 
• No association was seen between DLX2 expression and initial D’Amico risk, 
initial serum PSA, Gleason score, castrate resistance, CaPSS or OS. 
 
MYO6 
• Increased cell membrane MYO6 expression showed a positive association 
with initial D’Amico risk at diagnosis (χ2=14.667, p=0.001) and initial 
Gleason score at diagnosis (χ2=6.808, p=0.009). 
• No association was seen between MYO6 expression and initial serum PSA, 
castrate resistance, metastasis development, CaPSS or OS. 
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PAICS 
• Cytoplasmic PAICS protein expression showed no association with PAICS 
expression, initial D’Amico risk, initial serum PSA, Gleason score, castrate 
resistance, metastasis development, CaPSS or OS. 
 
Ki67  
• Increased nuclear Ki67 expression showed a negative association with OS (χ
2=8.481, p=0.004) and CaPSS (χ2=5.069, p=0.024) and a positive 
association with metastatic disease (χ2=4.822, p=0.028) and castrate 
resistance (χ2=4.838, p=0.028). 
• Subsequent multivariate Cox regression analysis demonstrated that Ki67 
contributed additional predictive ability to PSA concentration and Gleason 
score for CaPSS (HR=2.190, p=0.05, 95%CI=1.001-4.792) and metastasis risk 
(HR=2.746, p=0.046, 95%CI=1.020-7.390).  
• No association was seen between Ki67 expression and initial serum PSA, 
D’Amico risk or Gleason Score. 
 
P53 
• P53 protein was localised to the cytoplasm and nucleus of malignant prostate 
tissue. Increased P53 nuclear expression was negatively associated with 
CaPSS (χ2=3.897, p=0.048).  
• No association was seen between P53 (nuclear) or P53 (cytoplasmic) and 
initial serum PSA, D’Amico risk, Gleason Score, metastases development, 
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castrate resistance and OS. P53 (cytoplasmic) showed no association with 
CaPSS. 
CK5/6 
• Increased cytoplasmic CK5/6 expression showed positive association with 
initial D’Amico risk category (χ2=6.179, p=0.046). 
• No association was seen between CK5/6 expression and initial serum PSA, 
Gleason score, castrate resistance, metastasis development, CaPSS or OS. 
 
CMET 
• CMET expression was localised to the cytoplasm and cell membrane of CaP.  
• Increased cytoplasmic CMET expression showed positive association with 
metastasis development (χ2=16.208, p=0.00005) and initial D’Amico risk 
(χ2=6.513, p=0.039). 
• Multivariate Cox regression analysis demonstrated that this association was 
not independent of Gleason score and PSA concentration at diagnosis 
(HR=0.311, p=0.002, 95%CI=0.148-0.651).  
• No association was seen between cytoplasmic CMET and initial serum PSA, 
Gleason score, castrate resistance, CaPSS or OS. Increased membranous 
CMET expression showed positive association with initial serum PSA at 
diagnosis (χ2=8.336, p=0.015).  
• No association was seen between membranous CMET and initial D’Amico 
risk, Gleason score, castrate resistance, metastasis development, CaPSS or OS. 
 
Integrin alpha2 
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• Integrin alpha 2 expression was localised to the cytoplasm and cell membrane 
of CaP.  
• No association was seen between Integrin alpha 2 and initial D’Amico risk, 
initial serum PSA, Gleason score, castrate resistance, metastasis development, 
CaPSS or OS. 
 
TMPRSS-ERG 
• Increased TMPRSS-ERG expression was negatively associated with CaPSS 
(χ2=6.926, p=0.008). 
• No association was seen between TMPRSS-ERG expression and initial serum 
PSA, Gleason score, castrate resistance, metastasis development or OS. 
 
4.2 Biomarker combinations 
Individually PAICS and RACEMASE do not predict CaPSS. However, when both 
were present and scored positive they were highly predictive of CaPSS (χ2=13.65, 
p=0.0002) and metastasis formation (χ2=6.775, p=0.009). 
 
4.3 Initial results summary and rationale for further analysis 
As can be seen from the above results we have demonstrated that biomarkers selected 
using bioinformatics and targeted literature search are predictive of clinical outcome 
in prostate cancer. As is the focus of all translational research the aim is to contribute 
information that will confer direct clinical benefit to a patient group. We therefore 
identified prostate cancer specific death and the development of metastatic disease as 
the two most significant clinical outcomes that can occur during the disease pathway. 
In addition, we felt that as DLX2 is an entirely novel marker that it was important to 
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disseminate our findings in the form of publication. To do that we also needed to 
validate our cohort by demonstrating similar biomarker associations to those seen by 
other groups and we therefore elected to include our Ki67 data. After discussion with 
the editorial team at the British Journal of Cancer regarding the issue of Gleason 
grading pre- and post- the ISUP 2005 consensus (as described in section 3.7), we 
asked Geoffrey Hulman (Consultant Histopathologist, Nottingham University 
Hospitals NHS Trust), to re-score the cancer cohort to post-ISUP 2005 standards. 
Once this had taken place we repeated our statistical analysis, focussing on DLX2 and 
Ki67, the results of which can be found below in section 4.4. 
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4.4 Ki67 and DLX2 with ISUP 2005 histological review 
4.4.1 Ki67 and time to CaP-specific death 
Figure 4: Kaplan Meier Chart demonstrating the association between Ki67 and CaP-
specific death 
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4.4.2 Ki67 and time to metastases 
Figure 5. Kaplan Meier Chart demonstrating the association between Ki67 and time to 
development of metastases.
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4.4.3 DLX2 and time to CaP-specific death 
Figure 6: Kaplan Meier Chart demonstrating the association between DLX2 and CaP-
specific death 
 
 
  
  
64 
4.4.4 DLX2 and time to metastases 
Figure 7 Kaplan Meier Chart demonstrating the association between DLX2 and time 
to development of metastases 
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5.0 Discussion 
5.1 Overview 
This study examines biomarkers of prostate cancer that can be practically used to 
further enhance the current prognostic staging of this important disease. We employed 
highly sophisticated statistical techniques such as artificial neural network analysis to 
identify potential new markers. We also developed a large, clinically comprehensive 
tissue micro-array to allow quantification of relevant protein expression against 
multiple recorded clinical outcomes. 
 
We demonstrated several biomarkers with the potential to predict disease progression 
and clinical outcome in an unselected group of prostate cancer patients over an 
extended period of clinical follow up. In particular, we showed that the markers Ki67 
and DLX2 have a statistically significant relationship with key study outcomes 
prostate cancer mortality (Ki67 and DLX2) and prostate cancer metastases (DLX2). 
We also summarised the potential biological pathways where these markers may be 
involved in the pathogenesis of prostate cancer. 
 
Given that these markers are relatively easy to assay, and that tissue taken from 
diagnostic prostate biopsies is sufficient in volume to allow for this assay without 
compromising the ability to diagnose the disease our intention going forward is to set 
up a prospective trial examining whether the expression of KI67 and DLX2 at 
diagnosis could practically predict outcome of a patient’s prostate cancer, particularly 
in the ‘intermediate’ risk group where the decision to undergo radical treatment or 
active surveillance is a difficult one, with potentially extremely significant 
repercussions if the incorrect decision is made.  
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The techniques employed in this study have the capacity to be applied to other 
urological malignancies. For example, urothelial cancer is extremely prevalent, but 
with a wide-ranging clinical outcome, from fairly indolent disease to rapid 
development of metastases and death. In addition, in comparison to prostate cancer it 
has had only a fraction of the research effort applied to it, probably due to the lack of 
equivalent funding sources - prostate cancer has multiple successful charities that 
have provided financial backing over the last decade. It would therefore seem a 
logical next step to develop an appropriate tissue bank and clinical database to allow 
practical assessment of new biomarkers identified with similar methods to those we 
have used in this study. 
 
5.2 Background 
The development and progression of prostate cancer is an extremely complex process 
and a number of important factors are involved, including genetic abnormalities, 
oxidative stress and cellular inflammation, altered epithelial – stromal interaction and 
androgen receptor signalling. The diagnosis of prostate cancer is based on a 
combination of clinical signs, examination findings, molecular markers and 
histological examination of biopsy samples. While improvements are always being 
sought to make diagnosis a quicker, more reliable process with as few risks to the 
patient as possible it is essentially straightforward – a patient either has prostate 
cancer or does not. The complex part is predicting which patients are going to 
progress to life-threatening disease without treatment, and those that will not develop 
clinically-significant disease in their lifetime. Current risk stratification models are 
more accurate in predicting those with very low and very high risk, but are less able to 
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predict the clinical outcome for those in the intermediate group. In addition, once 
patients have undergone treatment the molecular biology of biochemical relapse, 
progression and the development of metastatic spread are still not fully understood. 
 
At present, single biomarkers are currently used for diagnostic and predictive 
assessment of prostate cancer. The most widely used and evidence-based is prostate-
specific antigen (PSA), a 34kD serine protease encoded by a gene on chromosome 19 
and uniquely produced by prostate epithelial cells. A raised PSA level can indicate an 
increased risk of prostate cancer, although presence of other factors such as urinary 
tract infection and significant lower urinary tract symptoms can cause similar rises. 
There is no absolute value above which prostate cancer is present, but studies have 
shown that a PSA of 4ng/ml confers approximately a 25% risk of cancer84. PSA is 
particularly useful in monitoring response to treatment in CaP. For example, a rise in 
PSA in a patient who has undergone radical treatment is an early indicator of disease 
recurrence. Another marker, less widely used and mainly as a diagnostic adjunct, is 
prostate cancer antigen-3 (PCA3). It is a non-coding segment of mRNA produced by 
prostate epithelial cells approximately 60 to 100 times more in prostate cancer than 
benign tissue. The most common assay is marketed as Progensa85 and samples for 
analysis are collected in the urine after prostatic massage and a ratio of PCA3 to PSA 
mRNA is calculated and a prostate cancer risk is determined.  
 
This study identifies several tumour biomarkers, selected using a bioinformatic ANN 
approach and literature survey, which provide clinically relevant information 
concerning prostate cancer progression and survival. 
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Development of metastasis was associated with increased expression of the tumour 
markers DLX2, Ki67 and CMET. DLX2 is entirely novel and this is the first study to 
identify it as a potential marker of disease progression in prostate cancer. The markers 
Ki67, P53 and TMPRSS-ERG are predictors of disease specific survival in CaP and 
we have validated this finding in the present study. Individually, Ki67 contributed 
predictive information additional to the PSA and histological Gleason score. 
Interestingly in some instances combining biomarkers strengthened predictive 
accuracy. For example, while neither PAICS nor Racemase demonstrated statistically 
significant association with clinical outcome in isolation, when combined and both 
scored positive they were shown to be highly predictive of disease specific survival 
and metastasis. 
      
The biomarkers tested here are functionally associated with cell replication, apoptosis, 
cell migration or tumour cell of origin and their relationships and our findings are 
discussed in detail below. 
 
5.3 Cellular proliferation markers and their application in prostate cancer 
We have demonstrated a clear association between the proliferation marker Ki67 and 
prostate cancer specific survival and time to metastases. It should be noted that when 
analysing the data, patients were only included if the appropriate endpoint (eg. 
metastases or death) was recorded in the clinical follow-up, and that there was an IHC 
result available for that particular marker (as with all TMA assessment some samples 
are lost during processing, and due to tissue heterogeneity multiple samples taken 
from the same core will not always show cancer). This means that for any particular 
marker the number of patients included was less than the entire cohort in the TMA – 
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individual figures can be seen in Table 8. This relationship was independent of 
whether the prostate tissue was scored on the pre- or post-ISUP 2005 histological 
Gleason grades. In addition, we demonstrated that Ki67 provides additional 
prognostic utility (HR:2.19) to the PSA and Gleason score, validating the study by 
Fisher et al.86 who recently reported that Ki67 independently adds significant 
predictive information (HR:2.78) in prostate biopsies. Only 6.6% of our cancer cohort 
had raised Ki67 and we propose that such patients could be counselled regarding an 
increased risk of death, metastasis and castrate resistance, particularly if they are 
being considered for an active surveillance programme. These findings fit with a 
hypothesis that tumour proliferation rates are a surrogate for tumour aggression.  
 
Assessment of cell proliferation in cancer has received much attention because 
proliferation is a key requirement for tumour growth and its progression. Unregulated 
cell turnover occurs as a result of genetic abnormalities at all stages of tumour 
development and can broadly be grouped by where in this pathway they occur. For 
example, alterations to genes such as ER-1B 87,88 and NKX3-189,90 have been linked to 
dysregulated cell proliferation. Loss or mutation of genes such as HPC1 (that codes 
for the tumour suppressor protein RNaseL) are thought to lead to altered apoptotic 
processes in response to cellular stress91,92. 
 
Ki67 is a nuclear proliferation marker that represents cell turnover and has been 
investigated extensively as a clinical marker, particularly in the field of breast cancer 
research where it has been used as an adjunct to assessing disease prognosis, 
predicting response to treatment and in disease surveillance. Results of studies, and its 
subsequent clinical application have been limited, however, by inconsistency in 
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immunohistochemical techniques and scoring boundaries93. This has been clearly 
demonstrated in a number of recent papers showing that factors such as tumour region 
selection while scoring, counting method and subjective assessment of staining 
intensity all affect outcome93–95. Even if these factors are accounted for (which is one 
of the goals of the Ki67 international reproducibility study93) then scoring boundaries 
need standardisation as in a recent review cutoffs were found to range from 0 to 28%. 
 
The biological mechanism of Ki67 is via its action as a key controller of the cell cycle, 
and is expressed in all active phases of the cell cycle.  During interphase, Ki67 can be 
exclusively detected within the nucleus, whereas in mitosis most of the protein is 
relocated to the surface of the chromosomes. The fact that the Ki-67 protein is present 
during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent from 
resting cells (G0), makes it an excellent marker for determining the so-called growth 
fraction of a given cell population96. 
 
Like in breast cancer, there has been a great deal of interest in the use of Ki67 as a 
prognostic marker in prostate cancer, and in various trials it has shown both univariate 
and multivariate clinical significance86,87,97–100.  For example, using a cutoff of >5% 
cancer nuclei positively stained, Ki67 is prognostic of cancer specific death in tissues 
derived by trans-urethral resection of prostate (TURP)87. Similar findings were 
obtained using a 10% nuclei cutoff in diagnostic biopsies86. A recent investigation 
found high (>6.2%) levels of histologically detected Ki67 were prognostic of disease 
specific death, metastasis and biochemical failure (rising PSA) in low to intermediate 
(PSA<20ng/ml) patients treated with a combination of short term ADT and 
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radiotherapy101. Ki67 is also a component of the Cell Cycle Progression signature 
proposed by the Transatlantic Prostate Group102.  
 
While the assessment of Ki67 expression with immunohistochemistry has the 
potential for providing a cost-effective and robust laboratory technique applicable to 
routinely processed pathology samples for similar reasons to breast cancer (as 
described above) it has so far failed to make the conversion from 
research/investigative tool into daily clinical use. It is likely, however, that with 
efforts to reach consensus in laboratory IHC techniques and with determining an 
agreed value for what level of expression should be deemed ‘positive’ that this marker 
will play an increasingly important role in prostate cancer risk stratification strategies. 
 
5.4 Cell cycle regulation   
Cell cycle regulation is a key arbiter of normal cellular growth, development and 
death. The markers P53 and DLX2 are both important proteins in this mechanism. We 
have demonstrated that there is an association between increased nuclear P53 
expression and reduced CaPSS. In addition, increased nuclear DLX2 expression 
showed a positive association with metastasis development independently of PSA 
concentration and Gleason score using multivariate Cox regression analysis. 
   
P53 is an extremely important tumour suppressor gene, with mutations seen in over 
50% of all human malignancies and is coded for on the short arm of chromosome 17. 
P53 exerts its effect at the G1/S cell cycle checkpoint where it can pause the cell cycle 
if it recognises DNA damage to allow repair and subsequent cycle progression, or if 
the damage is significant it can trigger apoptosis. When activated, p53 increases 
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expression of many other genes, most commonly through E2F protein family 
mediation. In particular it up regulates p21 that in turn complexes with the cyclin-
dependent kinases, which normally facilitate transition through the G1/S checkpoint, 
thus inhibiting their action.  
 
FIGURE 8: Cyclic control of p53 cell cycle checkpoint function by E2F family 
members. p53 becomes phosphorylated at ser315 by cell cycle-associated kinases. 
This provokes E2F1–3 to bind p53 displacing cyclin A interaction and inducing p53 
to become transcriptionally competent. As cyclin A and other kinase levels increase, 
E2F1–3 binding will be disrupted thereby reducing p53 activity103 
 
                                   
 
In addition to the relationship between p53 dysregulation and CaP further important 
associations have been demonstrated between PTEN (phosphatase and tensin 
homologue), which acts as a cell cycle regulator, and the development of prostate 
cancer. PTEN deletions have been demonstrated in 5% of localised CaP but over 30% 
of metastatic CaP104, suggesting it may be an important target in the molecular 
transition between organ confined and widespread disease.  
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Distal-less homeobox 2 (DLX2) is a transcription factor involved in cell cycle 
regulation and is one of a family of six known genes that are involved in embryonic 
development, tissue homeostasis, lymphocyte development, cell cycle and apoptosis. 
While only recently becoming a target of interest to cancer research scientists the 
evidence base linking the distal-less homeobox family to oncogenic processes is 
expanding rapidly, both in urological and non-urological cancers.  
 
The interaction between DLX2 and various cellular pathways is being investigated 
currently with one area of research examining its role in regulation of Transforming 
Growth Factor beta (TGF-β). TGF-β is a protein involved in proliferation and cellular 
differentiation in many cells and its dysregulation plays an integral part in the 
development and propagation of prostate cancer. The distal-less homeobox gene 
family has been implicated in triggering this dysregulation. A recent study105 showed 
that DLX2 is involved in shifting TGFβ from a tumour suppressor to a tumour 
promoting function by repressing TGFβRII and the cell cycle inhibitor p21CIP1, and 
simultaneously increasing the mitogenic transcription factor c-Myc and epidermal 
growth factor (EGF). The impact of this has been shown to increase tumour growth 
and metastasis formation in melanoma and lung cancer 
 
Another very interesting field of study is the relationship between DLX2 and cell 
senescence. Cellular senescence describes the process by which cells enter a period of 
growth arrest that essentially determines their life span. When senescence markers are 
triggered in a regulated fashion cells stop replicating and will succumb to apoptosis. 
However, if the process of senescence becomes dysregulated cells can continue to 
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replicate, despite the presence of cellular stressors or genetic aberration. It appears 
that DLX2 expression can switch cells into a ‘senescence-bypass’ phenotype, 
probably though mediation of the P53 and p21 cell cycle proteins.  
 
The p53 tumor suppressor pathway plays a pivotal role in the initiation of senescence 
cell cycle arrest. Triggers of function include DNA damage and telomere 
shortening106. DNA abnormalities activate a pivotal serine/threonine protein kinase 
called Ataxia Telangectasia Mutated (ATM) which is a key molecule in the regulation 
of cell cycle and DNA repair107. ATM activates the p53 tumor suppressor  through 
phosphorylation, which subsequently activates a cascade of interactions that result in 
the upregulation of p21, which suppresses inhibitory phosphorylation of the 
Retinoblastoma protein RB to arrest the cell cycle108 (Figure 5). 
 
DLX2 has been shown to down-regulate the p53-p21 cell cycle control pathway, both 
in ageing cells where shortened telomeres trigger senescence and in younger cells 
with laboratory-induced ionizing radiation DNA damage. This appears to be mediated 
by a reduction in expression of the ATM protein. Interestingly the same group has 
shown that in breast cancer (a malignancy with many similarities to prostate cancer) 
DLX2 and P53 mutations are generally mutually exclusive suggesting that 
overexpressed DLX2 may negate the need for p53 mutations in cancer cells. 
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Figure 8: The ATM molecular cascade: ATM and other molecular signals controlling 
cell-cycle checkpoints prompted by DNA damage (reused with permission from 
Nature Publishing Group, Licence number 4226361274939) 
 
 
  
Another key genetic abnormality in prostate cancer is TMPRSS2-ERG fusion, which 
is found to occur in at least 50% of CaP patients109. Our study has demonstrated that  
an increased TMPRSS-ERG expression is negatively associated with CaPSS 
(χ2=6.926, p=0.008). TMPRSS-ERG has been shown to promote cancer invasion and 
metastasis and some groups have linked TMPRSS2-ERG fusion to poorer overall 
prognosis, particularly in those patients in a ‘watchful waiting’ cohort110.  
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However, in early studies those patients undergoing surgery for their CaP 
demonstrated no clear difference in cancer specific survival caused by this gene 
fusion111.  The general consensus until recently was that TMPRSS2-ERG expression 
for predicting outcomes in prostate cancer was controversial, but it certainly became 
an established adjunct in the diagnosis of prostate cancer in men wishing to avoid a 
biopsy if possible. Studies have shown that raised urinary TMPRSS2-ERG levels (and 
in particular if combined with urinary PCA3 levels) have improved clinical decision 
curve analysis characteristics than PSA value alone in predicting the presence of 
significant and high grade prostate cancer112. 
 
However, more recently TMPRSS2-ERG gene fusion as a prognostic marker in 
prostate cancer has generated a greater evidence base113 and often seems to be 
associated with concomitant PTEN gene aberration in many situations, particularly 
those patients with high grade prostate cancer114. One theory that has been examined 
is that PTEN loss increases the susceptibility of prostatic epithelial cells to switch to a 
prostatic intraepithelial neoplasia (PIN) phenotype (Figure 6), which is a known 
precursor of prostate cancer. Subsequent TMPRSS2-ERG gene fusion promotes the 
final step of CaP development and increased activation of the androgen receptor, 
increasing cell turnover rate and likelihood of metastases115. 
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Figure 10: Model of prostate cancer progression showing ETS gene fusions as an 
enhancer lesion (reproduced with permission from the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology, www.atlasgeneticsoncology.org) 116. 
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Cooperation of unregulated pathways downstream of PTEN with effectors of ERG 
overexpression is likely a crucial event in the progression of an invasive and 
aggressive prostatic adenocarcinoma. Heterozygous genomic deletion of PTEN in 
benign prostatic precursors may represent an early event, and act as a driver lesion 
leading to proliferation, survival and genomic instability-all initial requisites of 
cancer. As a consequence of such heightened genomic instability, PTEN 
haploinsufficiency may facilitate the selective formation of the fusion gene with 
consequent acquisition of additional invasive properties. The presence of both 
rearrangements within a lesion is associated with accelerated disease progression and 
poor prognosis, indicating that synergistic molecular interactions exist between their 
complementary pathways. Continuing instability generates genotypic heterogeneity 
and diversity, such that subclones bearing PTEN homozygous deletions and amplified 
AR loci have further selective advantage for aggressive tumour progression, androgen 
escape and metastases. 
 
5.5 Tumour Lineage 
As described above there is evidence that genetic signatures commonly associated 
with embryonic stem cells (ESCs) are up regulated in the tumours of patients with 
more poorly differentiated prostate cancers60,61. Those prostate cancers expressing an 
ESC signature are more likely to be of higher Gleason grade and therefore have a 
poorer outcome than those cancers that do not. 
 
Eaton et al. have demonstrated an interesting relationship between the proportion of 
phenotypically positive prostate stem cells (PPSC) in the primary tumour and its 
derived metastases. Their work showed that PPSC was significantly higher in bone 
metastases compared to the primary prostate cancer63.  Further work by Columbel et 
al described an association between the stem cell markers integrin alpha-2 and -6 in 
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combination with c-met, with higher levels of expression predicting poorer CaP 
outcome64. 
 
We have confirmed that there is a relationship between the stem cell marker CMET 
and the development of CaP metastases, however we were unable to demonstrate a 
further association with integrin-alpha. 
 
It is likely that CaP may develop from progenitor cells resulting in cancers with basal 
and luminal lineages, and possibly conferring divergent disease pathways17. The basal 
epithelial compartment contains a pool of multipotent stem cells29,31,32 capable of 
differentiation into basal and secretory luminal epithelium, and an ‘intermediate’ 
amplification cell type33 and interestingly PTEN loss has been associated with basal 
cell derived prostate cancers117. These rare tumours have been considered fairly 
indolent in past studies, however increasingly there is evidence that this may not be 
the case and that in fact up to 44% of patients with basal cell derived prostate cancers 
in recent series have high risk disease117. 
 
Human prostate basal cells can be triggered to develop prostate cancer in vivo34 and in 
addition populations of luminal cells that retain some stem-cell like qualities have 
been identified. These may still be ‘early’ in the differentiation phase35, or derive 
from an entirely separate stem cell population17,37. Colombel et al.64 examined the 
expression of three putative stem cell markers: alpha2 and alpha6 integrin and CMET, 
in men with high risk CaP. They concluded that the proportion of stem cell-like 
cancer cells is predictive of metastatic bone progression, and that the accuracy was 
increased when either of the integrin markers was combined with CMET. Here, we 
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report that increased CMET expression is highly predictive of metastatic disease 
(χ2=16.208, p=0.00005), however did not find increased significance when combined 
with integrin alpha, possibly because very few patients concurrently expressed CMET 
and integrin alpha. CMET (or hepatocyte growth factor receptor) is coded for on 
chromosome 7 and acts as a tyrosine kinase that is appropriately active during 
embryonic development but if subject to genetic aberration is associated with tumour 
growth, angiogenesis and metastases. It triggers a series of downstream protein 
complexes, particularly the RAS, PI3K and STAT signal pathways. 
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Figure 11: CMET-mediated downstream cell signalling pathways (reused with 
permission from Nature Publishing Group, License number 4226380237905)118 
 
 
 
5.6 Genetic risk stratification 
Molecular classification techniques have identified candidate genes that might 
influence hormone/receptor biological pathways. Bioscience companies have been 
quick to recognise that array-based gene expression tools could potentially be used to 
guide treatment and predict outcomes. 
 
In breast cancer, early stratification studies of patients using gene expression profiling 
revealed an association between tumour biology genotype, tumour behaviour and 
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response to targeted therapy48. This approach has been refined and it is the case that 
whilst a single biomarker can inform about likely response to targeted therapy 
(theranostics eg. ER status and tamoxifen), panels of biomarkers are needed to inform 
about individualised risk of disease progression and survival. Risk assessment can be 
used to assist chemotherapy decision-making. For example, a 21 multi-gene PCR-
based assay was developed for predicting tumour recurrence in tamoxifen treated, 
node negative, ER expressing breast cancer119. This assay has been commercialised 
and marketed as the Oncotype DX Breast Cancer Test (Genomic Health) for 
predicting the likelihood of chemotherapy benefit in women with early stage breast 
cancer. Further assays such as Mammaprint and Prosigna have also been developed in 
breast cancer, and differ in their gene signatures and target population120. 
 
Similar techniques have been applied in prostate cancer and the resulting Oncotype 
DX Prostate Cancer test is a multigene PCR-based assay that assesses risk of disease 
progression in patients with apparent low risk disease. This 17 gene profile assesses 4 
distinct biological targets: the androgen pathway, cellular organisation, proliferation 
and stromal response121. This assay gives a ‘genomic prostate score’ (GPS) that 
predicts the likelihood of high grade or high stage disease at the time of diagnosis122. 
This array, like its competitors ‘Prolaris’ and ‘Decipher’ is not yet widely used and a 
recent systematic review concluded that they have yet to clearly demonstrate any 
significant advantage over more established predictive nomograms as a general 
clinical application39. 
 
Multi-gene/multi-protein biomarker panels are likely to be the mainstay of risk 
stratification and prognostic tools in the foreseeable future. However biomarker 
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assays have been significantly hindered by the known prostate cancer tumour multi-
focality and indeed intra-tumoral heterogeneity123,124. These two factors can cause 
difficulty when quantifying biomarkers as when limited tissue is being stained and 
scored it is possible to ‘miss’ other tumor foci of varying significance and in the 
presence of multiple clones of tumour cells with different characteristics, a single 
sample from one small tumour region might not be optimal for predicting a tumour’s 
aggressiveness125. There is an increasing awareness that multiple samples from a 
particular patient may need to be analysed to generate a ‘representative’ biomarker 
score. 
 
Further work employing hierarchical clustering techniques has identified expression 
of the gene product of Hey2 as being an independent predictor of biochemical failure, 
local recurrence and distant metastasis in prostate cancer126. The same group has 
demonstrated another gene (CYP4Z1) as an independent predictor of indolent disease. 
 
5.7 Limitations 
As with many studies there were limitations in this project that need to be 
acknowledged to allow accurate, informed opinion to be developed when assessing 
the work’s validity. 
 
The majority of tissue incorporated in the TMA, and thus exposed to IHC was from 
patients who underwent TURP rather than diagnostic biopsy. While we have 
described above that current guidelines state that patient’s diagnosed with CaP from 
TURP should be treated in the same way as biopsy-proven cancer, in practice patients 
undergoing TURP are older than men undergoing raised PSA-driven biopsy and 
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therefore are more likely to have higher volume and more aggressive disease. This is 
reflected in our high proportion of Gleason 8 and above cancer (and therefore high-
risk disease), which is not reflective of current trends. As a result, our data may be 
less applicable to those newly diagnosed intermediate risk patients who need further 
risk stratification to guide the choice between radical treatment and surveillance. An 
important priority for our group is to examine our markers again in a more up to date 
clinical cohort to ascertain whether the same results will be found. 
 
Our study used a TMA to score for immuno-reactivity, which is an established and 
validated method employed to process large numbers of patient’s tissue in an efficient 
manner. However staining can sometimes be unreliable or misleading as due to 
tumour heterogeneity samples can be missed when only staining a very thin tissue 
sample removed from the TMA with a microtome (as described above). 
 
6.0 Conclusion 
There is a need for more accurate markers of disease outcome in prostate cancer. 
Currently many patients undergo highly invasive and expensive treatments that carry 
significant side effects that may have been unnecessary, as their disease would never 
have become clinically apparent. Others will be stratified as low or intermediate risk 
but will subsequently develop highly aggressive disease with its attendant morbidity 
and mortality. 
 
This study has demonstrated several biomarkers with the potential to predict disease 
progression and clinical outcome in an unselected group of prostate cancer patients 
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over an extended period of clinical follow up. Several of the markers have a known 
biological function and disease mechanism including Ki67, P53 and DLX2.  
 
We have successfully added to the scientific literature by confirming that Ki67 is 
indeed associated with clinical outcome in CaP and we are the first group to identify 
the novel marker DLX2 as having prognostic utility in this disease, particularly 
showing great promise in predicting metastatic disease.  
 
Understanding the cell lineage of prostate cancer and applying the highly successful 
techniques used in breast cancer research has led to the development of gene signature 
arrays that reveal different molecular classifications in CaP. Emerging evidence 
suggests that molecular phenotyping is possible in prostate cancer and identification 
of distinct subtypes may allow personalised risk stratification way beyond that 
currently available.  
 
While initial results are promising, further work is required to define a robust panel of 
predictive markers in prostate cancer; this may involve selection of 
predictive/prognostic biomarkers that inform about the potential biological behaviour 
of circulating and disseminated tumour cells in addition to those detected in the 
primary organ (prostate).  
 
The use of gene expression arrays coupled with bioinformatic techniques has led to 
the identification of clinically useful multigene PCR assays and protein-based 
biomarkers. The former are generally more complex and require specialised tissue 
processing. Protein based assays are mostly applied to routinely processed 
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histological based samples or liquid samples. Currently, all would be used in-
conjunction with nomograms and risk algorithms currently employed by clinicians 
managing patients with prostate cancer. 
 
As we have demonstrated that DLX2 and Ki67 have prognostic function in CaP when 
applied retrospectively to a TMA based population it is important that we now 
investigate their application in a prospective clinical trial. The techniques required to 
quantify the protein expression of each biomarker (immunohistochemistry) are used 
widely in most mainstream NHS diagnostic laboratories and as prostate cancer is 
diagnosed through multi-core biopsy or transurethral resection of prostate (TURP) 
there is likely to be no logistical problem in acquiring sufficient tissue to assess 
biomarker expression. A major advantage of using these biomarkers is that their 
analysis and quantification are likely to be logistically and technically possible in a 
‘real world’ NHS setting, which unlike other first-world health systems such as the 
US is constrained financially and politically, making the uptake of expensive multi-
gene assays unlikely in the short to medium term. 
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8.0 Appendix  
SPSS data output for Ki67 and DLX2 examining associations between biomarker 
expression and CaP metastases and death 
 
Ki67 and time (months) to CaP-specific death 
 
Case Processing Summary	
Ki67with110positive	 Total N	 N of Events	
Censored	
N	 Percent	
.00	 57	 57	 0	 0.0%	
1.00	 8	 8	 0	 0.0%	
Overall	 65	 65	 0	 0.0%	
 
 
 
Means and Medians for Survival Time	
Ki67with110positi
ve	
Meana	 Median	
Estimate	 Std. Error	
95% Confidence Interval	
Estimate	 Std. Error	
95% Confidence Interval	
Lower Bound	 Upper Bound	 Lower Bound	 Upper Bound	
.00	 47.456	 4.429	 38.774	 56.138	 39.000	 4.847	 29.500	 48.500	
1.00	 26.375	 5.028	 16.520	 36.230	 21.000	 3.536	 14.070	 27.930	
Overall	 44.862	 4.018	 36.986	 52.737	 38.000	 4.031	 30.100	 45.900	
a. Estimation is limited to the largest survival time if it is censored.	
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Overall Comparisons	
 Chi-Square	 df	 Sig.	
Log Rank (Mantel-Cox)	 5.222	 1	 .022	
Breslow (Generalized 
Wilcoxon)	
3.396	 1	 .065	
Test of equality of survival distributions for the different levels of 
Ki67with110positive.	
 
  
  
98 
Survival Table	
Ki67with110positive	 Time	 Status	
Cumulative Proportion Surviving at 
the Time	 N of Cumulative 
Events	
N of Remaining 
Cases	Estimate	 Std. Error	
.00	 1	 2.000	 1.00	 .982	 .017	 1	 56	
2	 5.000	 1.00	 .965	 .024 2	 55	
3	 8.000	 1.00	 .	 .	 3	 54	
4	 8.000	 1.00	 .930	 .034	 4	 53	
5	 10.000	 1.00	 .	 .	 5	 52	
6	 10.000	 1.00	 .895	 .041	 6	 51	
7	 11.000	 1.00	 .877	 .043	 7	 50 
8	 13.000	 1.00	 .860	 .046	 8	 49	
9	 15.000	 1.00	 .	 .	 9	 48	
10	 15.000	 1.00	 .825	 .050	 10	 47	
11	 17.000	 1.00	 .	 .	 11	 46	
12	 17.000	 1.00	 .789	 .054	 12	 45	
13	 19.000	 1.00	 .	 .	 13	 44	
14	 19.000	 1.00	 .754	 .057	 14	 43	
15	 20.000	 1.00	 .737	 .058	 15	 42	
16	 28.000	 1.00	 .	 .	 16	 41	
17	 28.000	 1.00	 .702	 .061	 17	 40	
18	 29.000	 1.00	 .684	 .062	 18	 39	
19	 30.000	 1.00	 .667	 .062	 19	 38	
20	 31.000	 1.00	 .	 .	 20	 37	
21	 31.000	 1.00	 .632	 .064	 21	 36	
22	 32.000	 1.00	 .	 .	 22	 35	
23	 32.000	 1.00	 .	 .	 23	 34	
24	 32.000	 1.00	 .579	 .065	 24	 33	
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25	 34.000	 1.00	 .561	 .066	 25	 32	
26	 35.000	 1.00	 .544	 .066	 26	 31	
27	 38.000	 1.00	 .526	 .066	 27	 30	
28	 39.000	 1.00	 .	 .	 28	 29	
29	 39.000	 1.00	 .	 .	 29	 28	
30	 39.000	 1.00	 .474	 .066	 30	 27	
31	 42.000	 1.00	 .456	 .066	 31	 26	
32	 43.000	 1.00	 .439	 .066	 32	 25	
33	 46.000	 1.00	 .421	 .065	 33	 24	
34	 47.000	 1.00	 .404	 .065	 34	 23	
35	 48.000	 1.00	 .	 .	 35	 22	
36	 48.000	 1.00	 .368	 .064	 36	 21	
37	 50.000	 1.00	 .351	 .063	 37	 20	
38	 53.000	 1.00	 .333	 .062	 38	 19	
39	 55.000	 1.00	 .	 .	 39	 18	
40	 55.000	 1.00	 .298	 .061	 40	 17	
41	 56.000	 1.00	 .281	 .060	 41	 16	
42	 57.000	 1.00	 .263	 .058	 42	 15	
43	 58.000	 1.00	 .246	 .057	 43	 14	
44	 61.000	 1.00	 .228	 .056	 44	 13	
45	 72.000	 1.00	 .211	 .054	 45	 12	
46	 83.000	 1.00	 .193	 .052	 46	 11	
47	 86.000	 1.00	 .175	 .050	 47	 10	
48	 88.000	 1.00	 .158	 .048	 48	 9	
49	 89.000	 1.00	 .140	 .046	 49	 8	
50	 90.000	 1.00	 .123	 .043	 50	 7	
51	 94.000	 1.00	 .105	 .041	 51	 6	
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52	 104.000	 1.00	 .088	 .037	 52	 5	
53	 106.000	 1.00	 .070	 .034	 53	 4	
54	 112.000	 1.00	 .053	 .030	 54	 3	
55	 115.000	 1.00	 .035	 .024	 55	 2	
56	 121.000	 1.00	 .018	 .017	 56	 1	
57	 140.000	 1.00	 .000	 .000	 57	 0	
1.00	 1	 8.000	 1.00	 .875	 .117	 1	 7	
2	 13.000	 1.00	 .750	 .153	 2	 6	
3	 19.000	 1.00	 .625	 .171	 3	 5	
4	 21.000	 1.00	 .500	 .177	 4	 4	
5	 24.000	 1.00	 .375	 .171	 5	 3	
6	 35.000	 1.00	 .250	 .153	 6	 2	
7	 44.000	 1.00	 .125	 .117	 7	 1	
8	 47.000	 1.00	 .000	 .000	 8	 0	
 
 
Ki67 and time (months) to metastases 
 
 
 
Case Processing Summary	
Ki67with110positive	 Total N	 N of Events	
Censored	
N	 Percent	
.00	 45	 45	 0	 0.0%	
1.00	 5	 5	 0	 0.0%	
Overall	 50	 50	 0	 0.0%	
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Survival Table	
Ki67with110positive	 Time	 Status	
Cumulative Proportion Surviving at 
the Time	 N of Cumulative 
Events	
N of Remaining 
Cases	Estimate	 Std. Error	
.00	 1	 .000	 1.00	 .978	 .022	 1	 44	
2	 1.000	 1.00	 .956	 .031	 2	 43	
3	 2.000	 1.00	 .933	 .037	 3	 42	
4	 3.000	 1.00	 .	 .	 4	 41	
5	 3.000	 1.00	 .889	 .047	 5	 40	
6	 4.000	 1.00	 .867	 .051	 6	 39	
7	 7.000	 1.00	 .844	 .054	 7	 38	
8	 12.000	 1.00	 .822	 .057	 8	 37	
9	 17.000	 1.00	 .800	 .060	 9	 36	
10	 18.000	 1.00	 .	 .	 10	 35	
11	 18.000	 1.00	 .756	 .064	 11	 34	
12	 19.000	 1.00	 .733	 .066	 12	 33	
13	 20.000	 1.00	 .711	 .068	 13	 32	
14	 22.000	 1.00	 .	 .	 14	 31	
15	 22.000	 1.00	 .667	 .070	 15	 30	
16	 23.000	 1.00	 .644	 .071	 16	 29	
17	 24.000	 1.00	 .	 .	 17	 28	
18	 24.000	 1.00	 .	 .	 18	 27	
19	 24.000	 1.00	 .578	 .074	 19	 26	
20	 26.000	 1.00	 .	 .	 20	 25	
21	 26.000	 1.00	 .533	 .074	 21	 24	
22	 27.000	 1.00	 .511	 .075	 22	 23	
23	 29.000	 1.00	 .489	 .075	 23	 22	
24	 30.000	 1.00	 .467	 .074	 24	 21	
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25	 31.000	 1.00	 .444	 .074	 25	 20	
26	 32.000	 1.00	 .422	 .074	 26	 19	
27	 35.000	 1.00	 .400	 .073	 27	 18	
28	 37.000	 1.00	 .378	 .072	 28	 17	
29	 43.000	 1.00	 .356	 .071	 29	 16	
30	 45.000	 1.00	 .333	 .070	 30	 15	
31	 50.000	 1.00	 .311	 .069	 31	 14	
32	 52.000	 1.00	 .289	 .068	 32	 13	
33	 68.000	 1.00	 .267	 .066	 33	 12	
34	 79.000	 1.00	 .244	 .064	 34	 11	
35	 80.000	 1.00	 .222	 .062	 35	 10	
36	 84.000	 1.00	 .200	 .060	 36	 9	
37	 85.000	 1.00	 .178	 .057	 37	 8	
38	 102.000	 1.00	 .156	 .054	 38	 7	
39	 103.000	 1.00	 .133	 .051	 39	 6	
40	 105.000	 1.00	 .111	 .047	 40	 5	
41	 110.000	 1.00	 .089	 .042	 41	 4	
42	 113.000	 1.00	 .067	 .037	 42	 3	
43	 125.000	 1.00	 .044	 .031	 43	 2	
44	 127.000	 1.00	 .022	 .022	 44	 1	
45	 139.000	 1.00	 .000	 .000	 45	 0	
1.00	 1	 8.000	 1.00	 .800	 .179	 1	 4	
2	 14.000	 1.00	 .	 .	 2	 3	
3	 14.000	 1.00	 .400	 .219	 3	 2	
4	 19.000	 1.00	 .200	 .179	 4	 1	
5	 34.000	 1.00	 .000	 .000	 5	 0	
 
 
  
103 
Means and Medians for Survival Time	
Ki67with110positi
ve	
Meana	 Median	
Estimate	 Std. Error	
95% Confidence Interval	
Estimate	 Std. Error	
95% Confidence Interval	
Lower Bound	 Upper Bound	 Lower Bound	 Upper Bound	
.00	 45.467	 5.909	 33.885	 57.049	 29.000	 3.912	 21.332	 36.668	
1.00	 17.800	 4.409	 9.158	 26.442	 14.000	 3.286	 7.559	 20.441	
Overall	 42.700	 5.457	 32.003	 53.397	 26.000	 3.094	 19.937	 32.063	
a. Estimation is limited to the largest survival time if it is censored.	
 
 
Overall Comparisons	
 Chi-Square	 df	 Sig.	
Log Rank (Mantel-Cox)	 5.058	 1	 .025	
Breslow (Generalized 
Wilcoxon)	
3.825	 1	 .050	
Test of equality of survival distributions for the different levels of 
Ki67with110positive.	
 
 
DLX2 and time (months) to CaP-specific death 
 
Case Processing Summary	
DLX2with10cutoff	 Total N	 N of Events	
Censored	
N	 Percent	
.00	 23	 23	 0	 0.0%	
1.00	 61	 61	 0	 0.0%	
Overall	 84	 84	 0	 0.0%	
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Survival Table	
DLX2with10cutoff	 Time	 Status	
Cumulative Proportion Surviving at 
the Time	 N of Cumulative 
Events	
N of Remaining 
Cases	Estimate	 Std. Error	
.00	 1	 8.000	 1.00	 .	 .	 1	 22	
2	 8.000	 1.00	 .913	 .059	 2	 21	
3	 11.000	 1.00	 .870	 .070	 3	 20	
4	 17.000	 1.00	 .826	 .079	 4	 19	
5	 20.000	 1.00	 .783	 .086	 5	 18	
6	 22.000	 1.00	 .739	 .092	 6	 17	
7	 30.000	 1.00	 .696	 .096	 7	 16	
8	 31.000	 1.00	 .652	 .099	 8	 15	
9	 32.000	 1.00	 .609	 .102	 9	 14	
10	 38.000	 1.00	 .565	 .103	 10	 13	
11	 42.000	 1.00	 .522	 .104	 11	 12	
12	 43.000	 1.00	 .478	 .104	 12	 11	
13	 48.000	 1.00	 .435	 .103	 13 10	
14	 61.000	 1.00	 .391	 .102	 14	 9	
15	 77.000	 1.00	 .348	 .099	 15	 8	
16	 82.000	 1.00	 .304	 .096	 16	 7	
17	 83.000	 1.00	 .261	 .092	 17	 6	
18	 86.000	 1.00	 .217	 .086	 18	 5	
19	 88.000	 1.00	 .174	 .079	 19	 4	
20	 90.000	 1.00	 .130	 .070	 20	 3	
21	 112.000	 1.00	 .087	 .059	 21	 2	
22	 133.000	 1.00	 .043	 .043	 22	 1	
23	 140.000	 1.00	 .000	 .000	 23	 0	
1.00	 1	 1.000	 1.00	 .984	 .016	 1	 60	
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2	 2.000	 1.00	 .967	 .023	 2	 59	
3	 5.000	 1.00	 .951	 .028	 3	 58	
4	 8.000	 1.00	 .934	 .032	 4	 57	
5	 10.000	 1.00	 .918	 .035	 5	 56	
6	 11.000	 1.00	 .902	 .038	 6	 55	
7	 13.000	 1.00	 .	 .	 7	 54	
8	 13.000	 1.00	 .869	 .043	 8	 53	
9	 15.000	 1.00	 .852	 .045	 9	 52	
10	 17.000	 1.00	 .836	 .047	 10	 51	
11	 19.000	 1.00	 .	 .	 11	 50	
12	 19.000	 1.00	 .	 .	 12	 49	
13	 19.000	 1.00	 .787	 .052	 13	 48	
14	 21.000	 1.00	 .	 .	 14	 47	
15	 21.000	 1.00	 .754	 .055	 15	 46	
16	 24.000	 1.00	 .	 .	 16	 45	
17	 24.000	 1.00	 .721	 .057	 17	 44	
18	 25.000	 1.00	 .705	 .058	 18	 43	
19	 26.000	 1.00	 .689	 .059	 19	 42	
20	 28.000	 1.00	 .	 .	 20	 41	
21	 28.000	 1.00	 .656	 .061	 21	 40	
22	 29.000 1.00	 .639	 .061	 22	 39	
23	 31.000	 1.00	 .623	 .062	 23	 38	
24	 32.000	 1.00	 .	 .	 24	 37	
25	 32.000	 1.00	 .	 .	 25	 36	
26	 32.000	 1.00	 .574	 .063	 26	 35	
27	 33.000	 1.00	 .557	 .064	 27	 34	
28	 34.000	 1.00	 .541	 .064	 28	 33	
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29	 38.000	 1.00	 .525	 .064	 29	 32	
30	 40.000	 1.00	 .508	 .064	 30	 31	
31	 41.000	 1.00	 .492	 .064	 31	 30	
32	 42.000	 1.00	 .475	 .064	 32	 29	
33	 44.000	 1.00	 .459	 .064	 33	 28	
34	 46.000	 1.00	 .	 .	 34	 27	
35	 46.000	 1.00	 .426	 .063	 35	 26	
36	 47.000	 1.00	 .410	 .063	 36	 25	
37	 48.000	 1.00	 .393	 .063	 37	 24	
38	 50.000	 1.00	 .377	 .062	 38	 23	
39	 53.000	 1.00	 .361	 .061	 39	 22	
40	 54.000	 1.00	 .344	 .061	 40	 21	
41	 55.000	 1.00	 .	 .	 41	 20	
42	 55.000	 1.00	 .311	 .059	 42	 19	
43	 56.000	 1.00	 .	 .	 43	 18	
44	 56.000	 1.00	 .279	 .057	 44	 17	
45	 57.000	 1.00	 .262	 .056	 45	 16	
46	 58.000	 1.00	 .246	 .055	 46	 15	
47	 59.000	 1.00	 .230	 .054	 47	 14	
48	 60.000	 1.00	 .213	 .052	 48	 13	
49	 66.000	 1.00	 .197	 .051	 49	 12	
50	 67.000	 1.00	 .180	 .049	 50	 11	
51	 72.000	 1.00	 .164	 .047	 51	 10	
52	 76.000	 1.00	 .	 .	 52	 9	
53	 76.000	 1.00	 .131	 .043	 53	 8	
54	 83.000	 1.00	 .115	 .041	 54	 7	
55	 89.000	 1.00	 .098	 .038	 55	 6	
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56	 104.000	 1.00	 .082	 .035	 56	 5	
57	 106.000	 1.00	 .066	 .032	 57	 4	
58	 115.000	 1.00	 .049	 .028	 58	 3	
59	 116.000	 1.00	 .033	 .023	 59	 2	
60	 121.000	 1.00	 .016	 .016	 60	 1	
61	 123.000	 1.00	 .000	 .000	 61	 0	
 
 
Means and Medians for Survival Time	
DLX2with10cutof
f	
Meana	 Median	
Estimate	 Std. Error	
95% Confidence Interval	
Estimate	 Std. Error	
95% Confidence Interval	
Lower Bound	 Upper Bound	 Lower Bound	 Upper Bound	
.00	 56.609	 8.233	 40.472	 72.746	 43.000	 7.985	 27.348	 58.652	
1.00	 45.754	 3.942	 38.028	 53.481	 41.000	 6.345	 28.564	 53.436	
Overall	 48.726	 3.655	 41.562	 55.890	 42.000	 5.498	 31.225	 52.775	
a. Estimation is limited to the largest survival time if it is censored.	
 
 
Overall Comparisons	
 Chi-Square	 df	 Sig.	
Log Rank (Mantel-Cox)	 2.282	 1	 .131	
Breslow (Generalized 
Wilcoxon)	
.892	 1	 .345	
Test of equality of survival distributions for the different levels of 
DLX2with10cutoff.	
 
 
DLX2 and time (months) to metastases 
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Case Processing Summary	
DLX2with10cutoff	 Total N	 N of Events	
Censored	
N	 Percent	
.00	 19	 19	 0	 0.0%	
1.00	 42	 42	 0	 0.0%	
Overall	 61	 61	 0	 0.0%	
 
 
Survival Table	
DLX2with10cutoff	 Time	 Status	
Cumulative Proportion Surviving at 
the Time	 N of Cumulative 
Events	
N of Remaining 
Cases	Estimate	 Std. Error	
.00	 1	 3.000	 1.00	 .947	 .051	 1	 18	
2	 24.000	 1.00	 .	 .	 2	 17	
3	 24.000	 1.00	 .842	 .084	 3	 16	
4	 29.000	 1.00	 .789	 .094	 4	 15	
5	 30.000	 1.00	 .737	 .101	 5	 14	
6	 35.000	 1.00	 .684	 .107	 6	 13	
7	 42.000	 1.00	 .632	 .111	 7	 12	
8	 48.000	 1.00	 .579	 .113	 8	 11	
9	 52.000	 1.00	 .526	 .115	 9	 10	
10	 74.000	 1.00	 .474	 .115	 10	 9	
11	 79.000	 1.00	 .421	 .113	 11	 8	
12	 84.000	 1.00	 .368	 .111	 12	 7	
13	 85.000	 1.00	 .316	 .107	 13	 6	
14	 105.000	 1.00	 .263	 .101	 14 5	
15	 110.000	 1.00	 .211	 .094	 15	 4	
  
109 
16	 125.000	 1.00	 .158	 .084	 16	 3	
17	 127.000	 1.00	 .105	 .070	 17	 2	
18	 131.000	 1.00	 .053	 .051	 18	 1	
19	 139.000	 1.00	 .000	 .000	 19	 0	
1.00	 1	 .000	 1.00	 .	 .	 1	 41	
2	 .000	 1.00	 .	 .	 2	 40	
3	 .000	 1.00	 .929	 .040	 3	 39	
4	 1.000	 1.00	 .905	 .045	 4	 38	
5	 3.000	 1.00	 .881	 .050	 5	 37	
6	 4.000	 1.00	 .857	 .054	 6	 36	
7	 7.000	 1.00	 .833	 .058	 7	 35	
8	 11.000	 1.00	 .810	 .061	 8	 34	
9	 12.000	 1.00	 .786	 .063	 9	 33	
10	 14.000	 1.00	 .762	 .066	 10	 32	
11	 17.000	 1.00	 .738	 .068	 11	 31	
12	 18.000	 1.00	 .	 .	 12	 30	
13	 18.000	 1.00	 .690	 .071	 13	 29	
14	 19.000	 1.00	 .	 .	 14	 28	
15	 19.000	 1.00	 .643	 .074	 15	 27	
16	 20.000	 1.00	 .	 .	 16	 26	
17	 20.000	 1.00	 .595	 .076	 17	 25	
18	 22.000	 1.00	 .	 .	 18	 24	
19	 22.000	 1.00	 .548	 .077	 19	 23	
20	 23.000	 1.00	 .524	 .077	 20	 22	
21	 24.000	 1.00	 .500	 .077	 21	 21	
22	 26.000	 1.00	 .476	 .077	 22	 20	
23	 27.000	 1.00	 .452	 .077	 23	 19	
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24	 30.000	 1.00	 .	 .	 24	 18	
25	 30.000	 1.00	 .405	 .076	 25	 17	
26	 31.000	 1.00	 .381	 .075	 26	 16	
27	 36.000	 1.00	 .357	 .074	 27	 15	
28	 37.000	 1.00	 .333	 .073	 28	 14	
29	 43.000	 1.00	 .	 .	 29	 13 
30	 43.000	 1.00	 .	 .	 30	 12	
31	 43.000	 1.00	 .262	 .068	 31	 11	
32	 44.000	 1.00	 .238	 .066	 32	 10	
33	 45.000	 1.00	 .214	 .063	 33	 9	
34	 50.000	 1.00	 .190	 .061	 34	 8	
35	 64.000	 1.00	 .167	 .058	 35	 7	
36	 71.000	 1.00	 .143	 .054	 36	 6	
37	 80.000	 1.00	 .119	 .050	 37	 5	
38	 102.000	 1.00	 .095	 .045	 38	 4	
39	 103.000	 1.00	 .071	 .040	 39	 3	
40	 113.000	 1.00	 .048	 .033	 40	 2	
41	 115.000	 1.00	 .024	 .024	 41	 1	
42	 120.000	 1.00	 .000	 .000	 42	 0	
 
 
Means and Medians for Survival Time	
DLX2with10cutof
f	
Meana	 Median	
Estimate	 Std. Error	
95% Confidence Interval	
Estimate	 Std. Error	
95% Confidence Interval	
Lower Bound	 Upper Bound	 Lower Bound	 Upper Bound	
.00	 70.842	 9.809	 51.617	 90.067	 74.000	 22.490	 29.920	 118.080	
1.00	 36.357	 5.131	 26.301	 46.414	 24.000	 4.050	 16.061	 31.939	
Overall	 47.098	 5.062	 37.176	 57.021	 31.000	 4.462	 22.254	 39.746	
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a. Estimation is limited to the largest survival time if it is censored.	
 
 
Overall Comparisons	
 Chi-Square	 df	 Sig.	
Log Rank (Mantel-Cox)	 10.207	 1	 .001	
Breslow (Generalized 
Wilcoxon)	
9.475	 1	 .002	
Test of equality of survival distributions for the different levels of 
DLX2with10cutoff.	
 
 
4.4.5 Multivariate Analysis 
 
 
 
 
Cox Regression 
 
 
 
Omnibus Tests of Model Coefficientsa	
-2 Log 
Likelihood	
Overall (score)	 Change From Previous Step	 Change From Previous Block	
Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	
381.945	 5.619	 4	 .229	 4.629	 4	 .327	 4.629	 4	 .327	
a. Beginning Block Number 1. Method = Enter	
 
 
Variables in the Equation	
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 B	 SE	 Wald	 df	 Sig.	 Exp(B)	
95.0% CI for Exp(B)	
Lower	 Upper	
Ki67with110positive	 .890	 .408	 4.769	 1	 .029	 2.436	 1.096	 5.416	
PSAnew	 .000	 .000	 1.121	 1	 .290	 1.000	 1.000	 1.000	
Gleasoncategorised	 .018	 .222	 .006	 1	 .936	 1.018	 .659	 1.572	
Riskcategorised	 -.085	 .497	 .029	 1	 .864	 .919	 .347	 2.433	
 
 
Covariate Means	
 Mean	
Ki67with110positive	 .131	
PSAnew	 321.787	
Gleasoncategorised	 2.639	
Riskcategorised	 2.918	
 
 
 
 
 
Cox Regression 
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Omnibus Tests of Model Coefficientsa	
-2 Log 
Likelihood	
Overall (score)	 Change From Previous Step	 Change From Previous Block	
Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	
754.571	 20.937	 4	 .000	 20.840	 4	 .000	 20.840	 4	 .000	
a. Beginning Block Number 1. Method = Enter	
 
 
Variables in the Equation	
 B	 SE	 Wald	 df	 Sig.	 Exp(B)	
95.0% CI for Exp(B)	
Lower	 Upper	
Ki67with110positive	 .957	 .369	 6.729	 1	 .009	 2.605	 1.264	 5.368	
PSAnew	 .000	 .000	 .989	 1	 .320	 1.000	 1.000	 1.000	
Gleasoncategorised	 .133	 .166	 .646	 1	 .421	 1.143	 .825	 1.582	
Riskcategorised	 .771	 .344	 5.023	 1	 .025	 2.161	 1.102	 4.240	
 
 
Covariate Means	
 Mean	
Ki67with110positive	 .086	
PSAnew	 220.286	
Gleasoncategorised	 2.467	
Riskcategorised	 2.857	
 
 
 
 
Cox Regression 
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Omnibus Tests of Model Coefficientsa	
-2 Log 
Likelihood	
Overall (score)	 Change From Previous Step	 Change From Previous Block	
Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	
266.620	 9.628	 4	 .047	 7.507	 4	 .111	 7.507	 4	 .111	
a. Beginning Block Number 1. Method = Enter	
 
  
  
115 
Variables in the Equation	
 B	 SE	 Wald	 df	 Sig.	 Exp(B)	
95.0% CI for Exp(B)	
Lower	 Upper	
Ki67with110positive	 1.193	 .523	 5.191	 1	 .023	 3.296	 1.181	 9.196	
PSAnew	 .001	 .001	 2.282	 1	 .131	 1.001	 1.000	 1.002	
Gleasoncategorised	 .385	 .265	 2.109	 1	 .146	 1.469	 .874	 2.469	
Riskcategorised	 -.512	 .519	 .970	 1	 .325	 .600	 .217	 1.660	
 
 
Covariate Means	
 Mean	
Ki67with110positive	 .106	
PSAnew	 136.149	
Gleasoncategorised	 2.596	
Riskcategorised	 2.894	
 
 
 
Cox Regression 
 
Omnibus Tests of Model Coefficientsa	
-2 Log 
Likelihood	
Overall (score)	 Change From Previous Step	 Change From Previous Block	
Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	 Chi-square	 df	 Sig.	
307.007	 16.199	 4	 .003	 14.375	 4	 .006	 14.375	 4	 .006	
a. Beginning Block Number 1. Method = Enter	
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Variables in the Equation	
 B	 SE	 Wald	 df	 Sig.	 Exp(B)	
95.0% CI for Exp(B)	
Lower	 Upper	
PSAnew	 .001	 .001	 3.207	 1	 .073	 1.001	 1.000	 1.002	
Gleasoncategorised	 .081	 .257	 .098	 1	 .755	 1.084	 .654	 1.795	
Riskcategorised	 -.147	 .525	 .078	 1	 .780	 .864	 .309	 2.414	
DLX2with10cutoff	 1.013	 .337	 9.038	 1	 .003	 2.754	 1.423	 5.332	
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Covariate Means	
 Mean	
PSAnew	 113.415	
Gleasoncategorised	 2.604	
Riskcategorised	 2.887	
DLX2with10cutoff	 .642	
 
